ZA200302030B - Aliphatic nitrogen-containing 5-membered ring compound. - Google Patents
Aliphatic nitrogen-containing 5-membered ring compound. Download PDFInfo
- Publication number
- ZA200302030B ZA200302030B ZA200302030A ZA200302030A ZA200302030B ZA 200302030 B ZA200302030 B ZA 200302030B ZA 200302030 A ZA200302030 A ZA 200302030A ZA 200302030 A ZA200302030 A ZA 200302030A ZA 200302030 B ZA200302030 B ZA 200302030B
- Authority
- ZA
- South Africa
- Prior art keywords
- group
- substituted
- cyano
- trans
- lower alkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 163
- -1 di- substituted amino group Chemical group 0.000 claims description 98
- 125000000217 alkyl group Chemical group 0.000 claims description 91
- 125000001424 substituent group Chemical group 0.000 claims description 78
- 125000004122 cyclic group Chemical group 0.000 claims description 59
- 125000003277 amino group Chemical group 0.000 claims description 57
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 45
- LNWWQYYLZVZXKS-UHFFFAOYSA-N 1-pyrrolidin-1-ylethanone Chemical compound CC(=O)N1CCCC1 LNWWQYYLZVZXKS-UHFFFAOYSA-N 0.000 claims description 44
- 125000002619 bicyclic group Chemical group 0.000 claims description 35
- 125000002950 monocyclic group Chemical group 0.000 claims description 31
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims description 30
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims description 30
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 26
- 125000003545 alkoxy group Chemical group 0.000 claims description 25
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
- 125000000623 heterocyclic group Chemical group 0.000 claims description 21
- 125000004432 carbon atom Chemical group C* 0.000 claims description 20
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 16
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 16
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 16
- 125000006239 protecting group Chemical group 0.000 claims description 16
- 125000004076 pyridyl group Chemical group 0.000 claims description 16
- 229910052717 sulfur Inorganic materials 0.000 claims description 16
- 125000004434 sulfur atom Chemical group 0.000 claims description 16
- 125000002252 acyl group Chemical group 0.000 claims description 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- 230000002401 inhibitory effect Effects 0.000 claims description 15
- 125000002757 morpholinyl group Chemical group 0.000 claims description 15
- 125000005936 piperidyl group Chemical group 0.000 claims description 15
- 125000000335 thiazolyl group Chemical group 0.000 claims description 15
- 125000004193 piperazinyl group Chemical group 0.000 claims description 14
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 13
- 125000005843 halogen group Chemical group 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 13
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 13
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 12
- 125000006085 pyrrolopyridyl group Chemical group 0.000 claims description 12
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 12
- 125000001544 thienyl group Chemical group 0.000 claims description 12
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 10
- 238000011321 prophylaxis Methods 0.000 claims description 10
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 10
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 10
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 125000002541 furyl group Chemical group 0.000 claims description 7
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 7
- 125000002883 imidazolyl group Chemical group 0.000 claims description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 7
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 7
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 7
- 125000005493 quinolyl group Chemical group 0.000 claims description 7
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 7
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 7
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 6
- 125000004043 oxo group Chemical group O=* 0.000 claims description 6
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 claims description 6
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 5
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 4
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims description 4
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 125000002636 imidazolinyl group Chemical group 0.000 claims description 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 claims description 4
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 4
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims description 4
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 125000005475 oxolanyl group Chemical group 0.000 claims description 4
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 4
- 125000002755 pyrazolinyl group Chemical group 0.000 claims description 4
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 4
- 125000005942 tetrahydropyridyl group Chemical group 0.000 claims description 4
- 125000001166 thiolanyl group Chemical group 0.000 claims description 4
- 125000001425 triazolyl group Chemical group 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 3
- 230000036961 partial effect Effects 0.000 claims description 3
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 3
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- APFSHVJSMPNIFS-JHJVBQTASA-N C1C[C@@H](C(=O)N(C)C)CC[C@@H]1NCC(=O)N1[C@H](C#N)CSC1 Chemical compound C1C[C@@H](C(=O)N(C)C)CC[C@@H]1NCC(=O)N1[C@H](C#N)CSC1 APFSHVJSMPNIFS-JHJVBQTASA-N 0.000 claims description 2
- SKNXGZVLZOLWJC-UMVBOHGHSA-N N1=CC([N+](=O)[O-])=CC=C1N[C@@H]1CC[C@@H](NCC(=O)N2[C@@H](CSC2)C#N)CC1 Chemical compound N1=CC([N+](=O)[O-])=CC=C1N[C@@H]1CC[C@@H](NCC(=O)N2[C@@H](CSC2)C#N)CC1 SKNXGZVLZOLWJC-UMVBOHGHSA-N 0.000 claims description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 2
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000004615 ingredient Substances 0.000 claims 2
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 claims 1
- LSGIVGPKBYNLDJ-RBSFLKMASA-N O=C([C@H]1CC[C@@H](CC1)NCC(=O)N1[C@@H](CSC1)C#N)N1CCOCC1 Chemical compound O=C([C@H]1CC[C@@H](CC1)NCC(=O)N1[C@@H](CSC1)C#N)N1CCOCC1 LSGIVGPKBYNLDJ-RBSFLKMASA-N 0.000 claims 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 claims 1
- 125000001245 hexylamino group Chemical group [H]N([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 239000002904 solvent Substances 0.000 description 34
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 22
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 229960001701 chloroform Drugs 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 239000007858 starting material Substances 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 229910052783 alkali metal Inorganic materials 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 229940086542 triethylamine Drugs 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 6
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 6
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 201000001421 hyperglycemia Diseases 0.000 description 5
- 150000007529 inorganic bases Chemical class 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 4
- VEPJDHDKXNUJLM-UHFFFAOYSA-N 4-n-(5-nitropyridin-2-yl)cyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1NC1=CC=C([N+]([O-])=O)C=N1 VEPJDHDKXNUJLM-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- LBAQSKZHMLAFHH-UHFFFAOYSA-N ethoxyethane;hydron;chloride Chemical compound Cl.CCOCC LBAQSKZHMLAFHH-UHFFFAOYSA-N 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- SWTCRXVGKJOXJA-DFWYDOINSA-N (4r)-1,3-thiazolidine-4-carboxamide;hydrochloride Chemical compound Cl.NC(=O)[C@@H]1CSCN1 SWTCRXVGKJOXJA-DFWYDOINSA-N 0.000 description 2
- WPMZIZVPJORINX-RXMQYKEDSA-N (4r)-3-(2-chloroacetyl)-1,3-thiazolidine-4-carbonitrile Chemical compound ClCC(=O)N1CSC[C@H]1C#N WPMZIZVPJORINX-RXMQYKEDSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 2
- 206010020710 Hyperphagia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 description 2
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 2
- 150000008046 alkali metal hydrides Chemical class 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 238000010531 catalytic reduction reaction Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- VKIRRGRTJUUZHS-UHFFFAOYSA-N cyclohexane-1,4-diamine Chemical compound NC1CCC(N)CC1 VKIRRGRTJUUZHS-UHFFFAOYSA-N 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 2
- 201000008980 hyperinsulinism Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 125000006518 morpholino carbonyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])N(C(*)=O)C1([H])[H] 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 235000020830 overeating Nutrition 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 125000005400 pyridylcarbonyl group Chemical group N1=C(C=CC=C1)C(=O)* 0.000 description 2
- 125000001422 pyrrolinyl group Chemical group 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- WFQDTOYDVUWQMS-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1 WFQDTOYDVUWQMS-UHFFFAOYSA-N 0.000 description 1
- WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
- BAZVFQBTJPBRTJ-UHFFFAOYSA-N 2-chloro-5-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(Cl)N=C1 BAZVFQBTJPBRTJ-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- CWUOUOOFTBACIX-MGCOHNPYSA-N C1C[C@@H](N)CC[C@@H]1C(=O)N1CCNCC1 Chemical compound C1C[C@@H](N)CC[C@@H]1C(=O)N1CCNCC1 CWUOUOOFTBACIX-MGCOHNPYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- WIWREAGEPDYPAR-UHFFFAOYSA-N Cl.Cl.C(C)(=O)N1CCCC1 Chemical compound Cl.Cl.C(C)(=O)N1CCCC1 WIWREAGEPDYPAR-UHFFFAOYSA-N 0.000 description 1
- KCCXQOCQKJQHDO-KOEDQZHSSA-N Cl.Cl.CC(=O)[C@H]1SCC(C#N)N1N[C@@H]1CC[C@@H](NC=2N=CC(=CC=2)[N+]([O-])=O)CC1 Chemical compound Cl.Cl.CC(=O)[C@H]1SCC(C#N)N1N[C@@H]1CC[C@@H](NC=2N=CC(=CC=2)[N+]([O-])=O)CC1 KCCXQOCQKJQHDO-KOEDQZHSSA-N 0.000 description 1
- KKKBKWOSLNICEJ-WYSYYCCVSA-N Cl.Cl.CCOC(=O)[C@H]1CC[C@H](N)CC1 Chemical compound Cl.Cl.CCOC(=O)[C@H]1CC[C@H](N)CC1 KKKBKWOSLNICEJ-WYSYYCCVSA-N 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 102100020751 Dipeptidyl peptidase 2 Human genes 0.000 description 1
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 1
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- VLJNHYLEOZPXFW-BYPYZUCNSA-N L-prolinamide Chemical compound NC(=O)[C@@H]1CCCN1 VLJNHYLEOZPXFW-BYPYZUCNSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- PMDCRZFIHUJVDF-ATZDWAIDSA-N N([C@@H]1CC[C@H](CC1)C(=O)N1CC2=CC=CC=C2C1)CC(=O)N1CSC[C@H]1C#N Chemical compound N([C@@H]1CC[C@H](CC1)C(=O)N1CC2=CC=CC=C2C1)CC(=O)N1CSC[C@H]1C#N PMDCRZFIHUJVDF-ATZDWAIDSA-N 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- LXTVJSUBFGZSKT-KYZUINATSA-N N[C@H]1CC[C@H](C(=O)OCC=C)CC1 Chemical compound N[C@H]1CC[C@H](C(=O)OCC=C)CC1 LXTVJSUBFGZSKT-KYZUINATSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- XZHIFHISBMRLGK-BZUAXINKSA-N O([C@H]1CC[C@@H](CC1)NCC(=O)N1[C@@H](CSC1)C#N)C1=CC=C(C#N)C=N1 Chemical compound O([C@H]1CC[C@@H](CC1)NCC(=O)N1[C@@H](CSC1)C#N)C1=CC=C(C#N)C=N1 XZHIFHISBMRLGK-BZUAXINKSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000056251 Prolyl Oligopeptidases Human genes 0.000 description 1
- 101710178372 Prolyl endopeptidase Proteins 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- JLCHNBRGUPQWKF-UHFFFAOYSA-J [OH-].[C+4].[OH-].[OH-].[OH-] Chemical compound [OH-].[C+4].[OH-].[OH-].[OH-] JLCHNBRGUPQWKF-UHFFFAOYSA-J 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- AUALQMFGWLZREY-UHFFFAOYSA-N acetonitrile;methanol Chemical compound OC.CC#N AUALQMFGWLZREY-UHFFFAOYSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 125000005236 alkanoylamino group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- OJHAHQJRQIOCFK-UHFFFAOYSA-N azane;chloroform;methanol Chemical compound N.OC.ClC(Cl)Cl OJHAHQJRQIOCFK-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical class OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
- 230000007691 collagen metabolic process Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229920001577 copolymer Chemical group 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 150000001934 cyclohexanes Chemical class 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 108090000212 dipeptidyl peptidase II Proteins 0.000 description 1
- MYTMXVHNEWBFAL-UHFFFAOYSA-L dipotassium;carbonate;hydrate Chemical compound O.[K+].[K+].[O-]C([O-])=O MYTMXVHNEWBFAL-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005059 halophenyl group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000005554 pyridyloxy group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- ALSCEGDXFJIYES-UHFFFAOYSA-N pyrrolidine-2-carbonitrile Chemical compound N#CC1CCCN1 ALSCEGDXFJIYES-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YIVQKLSACUDWHD-UHFFFAOYSA-N tert-butyl n-(1-methyl-4-oxocyclohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1(C)CCC(=O)CC1 YIVQKLSACUDWHD-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Landscapes
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
SPECIFICATION
ALIPHATIC NITROGEN-CONTAINING 5-MEMBERED RING COMPOUND he 5 TECHNICAL FIELD -The present invention relates to a novel aliphatic
E nitrogen-containing 5-membered ring compound having superior dipeptidylpeptidase IV (DPPIV) inhibitory action that is useful as a pharmaceutical.
Dipeptidylpeptidase IV (DPPIV) 1s a kind of serine protease that specifically hydrolyzes a dipeptide of Xaa-
Pro or Xaa-Ala (where Xaa may be any amino acid) from the N terminus of a polypeptide chain.
There are various reports regarding the role of DPPIV {also called to as CD26) in the body and its relationship with diseases (Holst, et al., Diabetes, Vol. 47, pp. 1663- 1670, 1998; Augustyns, et al., Current Medicinal Chemistry,
Vol. 6, pp. 311-327, 1999; Meester, et al., Immunol. Today,
Vol. 20, pp. 367-375, 1999; and, Fleicher, et al., Immunol.
Today, Vol. 15, pp. 180-184, 1994).
GLP-1 (glucagon-like peptide 1) is a peptide hormone that mainly acts in the pancreas after being secreted from the lower small intestine after meals, and primarily has the function of amplifying glucose-induced insulin secre-
B tion. In addition, there are several reports suggesting } that GLP-1 has an appetite- suppressing action. DPPIV hydrolyzes GLP-1, forming an inactive or antagonistic peptide.
Substances that inhibit the enzyme activity of DPPIV enhance the insulin secretion response to oral glucose loading by enhancing the action of intrinsic GLP-1, thereby improving impaired glucose tolerance.
Consequently, DPPIV inhibitors are considered to be useful for the prophylaxis and treatment of diabetes
(particularly type 2 diabetes), etc. Also, they are expected to be effective for the prophylaxis and treatment of other diseases induced or exacerbated by impaired glucose tolerance (including hyperglycemia (such as postprandial hyperglycemia), hyperinsulinemia, diabetes complications (such as renal disorder and neurological disorder), lipid metabolism disorder and obesity, etc.) .
Moreover, DPPIV inhibitors are also expected to be effective for the prophylaxis and treatment of diseases that are to be improved by enhancing the appetite-suppress- ing action of GLP-1 (including overeating and obesity, etc.) .
Also, DPPIV (CD26) present on the surface of T cells is strongly upregulated following T cell activation, and plays an important role in the activation and proliferation of T cells. T cell activity is known to be suppressed when
DPPIV (CD26) is blocked by antibodies or inhibitory sub- stances. Also, there has been an interest in the correla- tion between this enzyme and the pathological state in collagen metabolism disorders and diseases associated with abnormal immunity. For example, the DPPIV (CD26) positive rate of peripheral blood T cells is elevated in rheumatoid patients, and high levels of DPPIV activity have been detected in the urine of nephritis patients. Moreover,
DPPIV (CD26) is also thought to play an important role in the entry of HIV into lymphocytes. . ©
Consequently, substances that inhibit DPPIV (CD26) are expected to demonstrate prophylactic and therapeutic effects against diseases including autoimmune diseases ’ (such as arthritis and rheumatoid arthritis), osteoporosis, acquired immunodeficiency syndrome (AIDS) and rejections of transplanted organs and tissues.
On the other hand, as compounds having DPPIV inhibit- ory action, there are described 2-cyanopyrrolidine deriva- tives having DPPIV inhibitory action in International
Patent Laid-Open Publications Nos. W098/19998 and
WO00/34241.
The present invention provides a novel aliphatic nitrogen-containing 5-membered ring compound having an excellent DPPIV inhibitory action.
: As a result of earnest research to solve the above problems, the present inventors found a novel aliphatic nitrogen-containing 5-membered ring compound having DPPIV inhibitory action, thereby accomplished the present invention.
Namely, the present invention relates to an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I]:
RT rex YY nH-Crz-00-N 1)
CN wherein A represents -CH;- or -S-,
R! represents hydrogen atom, a lower alkyl group, a hydroxy lower alkyl group or a lower alkoxy lower alkyl group,
X represents -N(R))-, -O- or -CO-, where R® repre- sents hydrogen atom or a lower alkyl group, and ) R? represents (1) a cyclic group which may be substituted, where the cyclic group portion is (i) a monocyclic, bicyclic or tricyclic hydrocarbon group, Or (ii) a monocyclic, bicyclic or tricyclic hetero- cyclic group, or (2) an amino group which may be substituted, or a pharmaceutically acceptable salt thereof.
Although optical isomers based on an asymmetric carbon can be present in the objective compound [I] of the present invention, the present invention includes any of these optical isomers as well as mixtures thereof. In addition, although isomers (cis form or trans form) are also present based on the relative positions of substi- tuents with respect to the standard plane of a cyclic group, the present invention also includes any of these isomers as well as mixtures thereof.
In the present invention, examples of a lower alkyl group, a lower alkylthio group, a lower alkylsulfonyl group, a lower alkoxy group and a lower alkylamino group include linear or branched groups having 1 to 6 carbon atoms, and particularly those having 1 to 4 carbon atoms. And, exam- ples of a lower alkanoyl group and a lower alkanoylamino group include linear or branched groups having 2 to 7 carbon atoms, and particularly those having 2 to 5 carbon atoms. Examples of a lower cycloalkyl group and lower cycloalkenyl group include those having 3 to 8 carbon atoms, and particularly 3 to 6 carbon atoms. Examples of a lower alkylene group include linear or branched groups having 1 to 6 carbon atoms, and particularly 1 to 4 carbon atoms.
Examples of a lower alkenyl group and lower alkenylene group include those having 2 to 7 carbon atoms, and parti- cularly 2 to 5 carbon atoms. Further, examples of a halo- gen atom include fluorine, chlorine, bromine and iodine.
In the objective compound [I] of the present inven- tion, examples of hydrogen atom or a lower alkyl group represented by R® include hydrogen atom, methyl group, etc.
Among them, hydrogen atom is more preferred.
In the compound [I] of the present invention, exam- ples of "hydrogen atom, a lower alkyl group, a hydroxy lower alkyl group or lower alkoxy lower alkyl group" represented by R! include hydrogen atom, methyl group, hydroxymethyl group and methoxymethyl group. Among them,
: hydrogen atom is preferred. '
In the compound [I] of the present invention, a cyclic group portion of "a cyclic group which may be substituted" represented by R? includes (i) a monocyclic, bicyclic or tricyclic hydrocarbon group - and (ii) a monocyclic, bicyclic or tricyclic heterocyclic group.
Such monocyclic, bicyclic or tricyclic hydrocarbon groups include those having 3 to 15 carbon atoms, which may be partially or completely saturated.
Monocyclic hydrocarbon groups include those having 3 to 7 carbon atoms, examples of which include phenyl group, cyclohexyl group, cyclopentyl group, cyclobutyl group, cyclopropyl group, etc.
Bicyclic hydrocarbon groups include those having 9 to 11 carbon atoms, examples of which include an indanyl group, an indenyl group, a naphthyl group, a tetrahydronaphthyl group and partially or completely saturated cyclic groups thereof, etc.
Tricyclic hydrocarbon groups include those having 12 to 15 carbon atoms, examples of which include a fluorenyl group, an anthryl group, a phenanthryl group and partially or completely saturated cyclic groups thereof, etc.
Monocyclic, bicyclic or tricyclic heterocyclic groups include a monocyclic, bicyclic or tricyclic heterocyclic group containing 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom, which may be partially or completely saturated. }
Monocyclic heterocyclic groups include a heterocyclic group containing 1 or 2 hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom and comprising of a saturated or unsaturated 5- to 7-membered ring, examples of which include: pyrrolidinyl group, an imidazolidinyl group, a pyrazolidinyl group, an oxolanyl group, a thiolanyl group, a pyrrolinyl group, an imidazolinyl group, a pyrazolinyl group, a pyrrolyl group, an imidazolyl group, a pyrazolyl group, a triazolyl group, a tetrazolyl group, a furyl group, an oxazolyl group, an isoxazolyl group, an oxadiazolyl group, a thienyl group, a thiazolyl group, an isothiazolyl group, a thiadiazolyl group, a piperidyl group, a pipera- ’ 5 zinyl group, a morpholinyl group, a thiomorpholinyl group, a pyridyl group, a pyrimidinyl group, a pyrazinyl group, a " pyridazinyl group, a pyranyl group, a tetrahydropyridyl group, a dihydropyridazinyl group, a perhydroazepinyl group, a perhydrothiazepinyl and partially or completely saturated cyclic groups thereof, etc.
Bicyclic heterocyclic groups include a heterocyclic group containing 1 to 3 hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom and comprising two saturated or unsaturated 5- to 7-membered rings being fused, examples of which include: an indolinyl group, an isoindolinyl group, an indolyl group, an indazolyl group, an isoindolyl group, a benzimidazolyl group, a benzothiazolyl group, a benzoxazolyl group, a benzodioxolanyl group, a benzothienyl group, a benzofuryl group, a thienopyridyl group, a thiazolopyridyl group, a pyrrolopyridyl group, a dihydropyrrolopyridyl group, a quinolyl group, an isoquinolyl group, a quinoxalinyl group, : a quinazolinyl group, a phthalazinyl group, a cinnolinyl group, a chromanyl group, an isochromanyl group, a naphthyridinyl group and partially or completely saturated " cyclic groups thereof, etc. : Tricyclic heterocyclic groups include a heterocyclic group containing 1 to 4 hetero atoms selected from nitrogen - atom, oxygen atom and sulfur atom and comprising three ) 30 saturated or unsaturated 5- to 7-membered rings being fused, examples of which include: a benzoxolanopyrimidyl group, a B-carbolinyl group, a carbazolyl group, a phenothiazinyl group, a phenoxazinyl group and partially or completely saturated cyclic groups thereof, etc.
Among these cyclic groups (monocyclic, bicyclic or tricyclic hydrocarbon groups or monocyclic, bicyclic or tricyclic heterocyclic groups),
) “(i) a monocyclic hydrocarbon group having 3 to 7 carbon atoms, : (ii) a bicyclic hydrocarbon groups having 9 to 11 carbon : atoms,
i (iii) a monocyclic heterocyclic group containing 1 or 2 hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom, or
(iv) a bicyclic heterocyclic group containing 1 to 3 hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom and comprising two 5- to 7-membered rings being fused" is preferred, examples of which include: "phenyl group, cyclohexyl group, cyclopentyl group, cyclo- butyl group, cyclopropyl group, an indanyl group, an indenyl group, a naphthyl group, tetrahydronaphthyl, a pyrrolidinyl group, an imidazolidinyl group, a pyrazolidin- vl group, an oxolanyl group, a thiolanyl group, a pyrrol- inyl group, an imidazolinyl group, a pyrazolinyl group, a pyrrolyl group, an imidazolyl group, a pyrazolyl group, a triazolyl group, a tetrazolyl group, a furyl group, an oxazolyl group, an isoxazolyl group, an oxadiazolyl group, a thienyl group, a thiazolyl group, an isothiazolyl group, a thiadiazolyl group, a piperidyl group, a piperazinyl group, a morpholinyl group, a thiomorpholinyl group, a pyridyl group, a pyrimidinyl group, a pyrazinyl group, a pyridazinyl group, a pyranyl group, a tetrahydropyridyl . group, a dihydropyridazinyl group, a perhydroazepinyl group, a perhydrothiazepinyl group, an indolinyl group, an iso- indolinyl group, an indolyl group, an indazolyl group, an isoindolyl group, a benzimidazolyl group, a benzothiazolyl group, a benzoxazolyl group, a benzodioxolanyl group, a benzothienyl group, a benzofuryl group, a thiencpyridyl group, a thiazolopyridyl group, a pyrrolopyridyl group, a dihydropyrrolopyridyl group, a quinolyl group, an iso- quinolyl group, a quinoxalinyl group, a quinazolinyl group,
a phthalazinyl group, a cinnolinyl group, a chromanyl group, an isochromanyl group, a naphthyridinyl group and partially . or completely saturated cyclic groups thereof, etc.*.
Among them, more preferred examples include: "phenyl group, cyclohexyl group, a pyrrolidinyl group, a tetrazolyl group, a furyl group, a thienyl group, a thia- zolyl group, a piperidyl group, a piperazinyl group, a morpholinyl group, a thiomorpholinyl group, a pyridyl group, a pyrimidinyl group, a pyrazinyl group, a pyridazinyl group, a perhydroazepinyl group, an indolinyl group, an isoindol- inyl group, a benzothienyl group, a thienopyridyl group, a pyrrolopyridyl group, a dihydropyrrolopyridyl group, a quinolyl group, an isogquinolyl group, a quinoxalinyl group and partially or completely saturated cyclic groups thereof, etc.", and further preferred examples include: "a pyrrolidinyl group, a piperidyl group, a piperazinyl group, a morpholinyl group, a thiomorpholinyl group, a pyridyl group, a pyrimidinyl group, an indolinyl group, an isoindolinyl group, a pyrrolopyridyl group, a dihydro- pyrrolopyridyl group and partially or completely saturated cyclic groups thereof, etc."
Among them, particularly preferred examples include: "].-pyrrolidinyl group, 1l-piperidyl group, l-piperazinyl group, 4-morpholinyl group, 4-thiomorpholinyl group, 2- pyridyl group, 2-pyrimidinyl group, 2-isoindolinyl group, 1-indolinyl group, 2,3-dihydro-1H-pyrrolo[3,4-blpyridin-2- yl group, etc.". 3 ’ "A cyclic group (a monocyclic, bicyclic or tricyclic : hydrocarbon group or a monocyclic, bicyclic or tricyclic heterocyclic group) which may be substituted " represented by R? may be unsubstituted or have 1 to 3 substituents which are the same or different.
Substituents in the cyclic group are not particularly limited, and examples of which include substituents selected from the following "substituents of Group A".
Among them, "substituents of Group A'" are more preferred.
CC - 9 -
In the objective compound {I] of the present invention, "an amino group which may be substituted” represented by R? may be unsubstituted or may be an amino group having 1 or 2 substituents which are the same or different (a mono- or di-substituted amino group).
Co Substituents in the amino group are not particularly limited, and examples of which include substituents So selected from the following "substituents of Group B".
Among them, "substituents of Group B'" are more preferred. "An amino group which may be substituted" represented by R? is preferably a substituted amino group (a mono- or di-substituted amino group), and more specifically "an amino group substituted by 1 or 2 substituents which are the same or different and selected from the group consist- ing of a lower alkyl group (methyl group, ethyl group, isopropyl group, butyl group, etc.), a lower cycloalkyl group, a lower alkoxy-substituted lower alkyl group, a pyrimidinyl group, a thiazolyl group and a thiadiazolyl group" is preferred. Among them, "(i) an amino group di-substituted by substituents which are the same or different and selected from a lower alkyl group (methyl group, ethyl group, isopropyl group, butyl group, etc.), a lower cycloalkyl group and a lower alkoxy- substituted lower alkyl group; or (ii) an amino group mono-substituted by a substituent selected from a pyrimidinyl group, a thiazolyl group and a ‘thiadiazolyl group" is more preferred, and . "an amino group di-substituted by substituents which are the same or different and selected from a lower alkyl group (methyl group, ethyl group, isopropyl group, butyl group, etc.), a lower cycloalkyl group and a lower alkoxy-substi- tuted lower alkyl group" is particularly preferred. ----Substituents of Group A:-------c------
As substituents of Group A, the following substi- tuents are mentioned: a halogen atom (Cl, F, Br, etc.); cyano group; nitro group,
oxo group, hydroxy group, carboxy group; oxidyl group; amino group; carbamoyl group; aminosulfonyl group; a lower alkyl group; a lower alkoxy group; a lower alkanoyl group; a lower alkoxycarbonyl group; a lower alkoxy-substituted lower alkanoyl group; a lower alkoxycarbonyl-substituted ) . lower alkoxy group; a lower alkoxycarbonyl-substituted lower alkoxycarbonyl group; a lower alkylthio group; . Co a lower alkylsulfonyl group; a di-lower alkylamino-substituted lower alkoxy group; a di-lower alkylaminocarboxy group; a lower alkyl group substituted by group(s) selected from amino group, carbamoyl group, a halogen atom, hydroxy group, carboxy group, a lower alkoxy group and a mono- or di- substituted amino group (substituents in the substituted amino group portion are not particularly limited, and examples of which include substituents of Group C mentioned below.) ; a mono- or di-substituted amino group or a mono- or di- substituted carbamoyl group (substituents in the substituted amino group or substituted carbamoyl group are not particularly limited, and examples of which include substituents of Group C mentioned below.); a substituted or unsubstituted lower cycloalkyl group, a substituted or unsubstituted lower cycloalkyl-CO-, a substituted or unsubstituted lower cycloalkyl-lower alkyl : group, oo a substituted or unsubstituted phenyl group, a substituted or unsubstituted phenyl-O-, - a substituted or unsubstituted phenyl -CO-, a substituted or unsubstituted phenyl-lower alkyl group, a substituted or unsubstituted phenyl-O-lower alkyl group, a substituted or unsubstituted phenylsulfonyl group, a substituted or unsubstituted phenyl-lower alkoxy group, a substituted or unsubstituted phenyl-lower alkoxycarbonyl group,
a substituted or unsubstituted cycloalkenyl group (a cyclo- butenyl group, etc.), a substituted or unsubstituted bicyclic heterocyclic group. a substituted or unsubstituted monocyclic 5- or 6-membered heterocyclic group, a substituted or unsubstituted monocyclic 5- or 6-membered heterocyclic group-0-, a substituted or unsubstituted monocyclic 5- or 6-membered heterocyclic group-CO-, a substituted or unsubstituted monocyclic 5- or 6-membered heterocyclic group-CO-lower alkyl group, and a substituted or unsubstituted monocyclic 5- or 6-membered heterocyclic group-lower alkyl group (substituents in the substituted lower cycloalkyl group portion, substituted phenyl group portion, substituted lower cycloalkenyl group portion, substituted bicyclic heterocyclic group portion or substituted monocyclic 5- or 6 -membered heterocyclic group portion are not particularly limited, and examples of which include a halogen atom (Cl, F, Br, etc.), cyano group, nitro group, oxo group and substituents in the substituents of Group C mentioned below, etc.
Also, a monocyclic 5- or 6-membered heterocyclic group portion includes a monocyclic 5- or 6-membered heterocyclic group containing 1 or 2 hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom, and : specific examples include a piperidyl group, a piperazinyl group, a morpholinyl group, a pyridyl group, a pyrimidinyl group, a pyrazinyl group, a pyridazinyl group, a pyrrolidinyl group, an imidazolidinyl group, a pyrazolidinyl group, a pyrrolyl group, an imid- azolyl group, a pyrazolyl group, a thiazolyl group, a thiadiazolyl group, a thienyl group, etc.
Also, a bicyclic heterocyclic group portion includes a bicyclic heterocyclic group containing 1 to 3 hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom and comprising two 5- or 6-membered rings being fused, and examples of which include an isoindolinyl group, an - indolinyl group, etc.) ---Substituents group A' (particularly preferred substi- tuents of Group A) :---=---=<------
As more preferable substituents of Group A, the following substituents are mentioned: a halogen atom (Cl, etc.); cyano group; nitro group; oxo group; carbamoyl group; a lower alkyl group; a lower alkoxy group; a lower alkanoyl group; a lower alkoxycarbonyl group; a lower alkoxy-substituted lower alkyl group, a mono- or di-substituted amino group (a lower cycloalkyl- carbonyl-substituted amino group, etc.), a mono- or di-substituted carbamoyl group (a phenyl-substi- tuted carbamoyl group, etc.), a lower cycloalkyl-CO-, a substituted or unsubstituted phenyl group (phenyl group, a halophenyl group, etc.), a substituted or unsubstituted phenyl-lower alkyl group (a phenyl-lower alkyl group, a halophenyl-lower alkyl group, etc.), a substituted or unsubstituted monocyclic 5- or 6-membered heterocyclic group (a thienyl group, etc.), a substituted or unsubstituted monocyclic 5- or 6-membered heterocyclic group-0- (a pyrimidinyloxy group, a halo- pyrimidinyloxy group, etc.), and a substituted or unsubstituted monocyclic 5- or 6-membered heterocyclic group-CO- (a pyridylcarbonyl group, a thienyl- h carbonyl group, etc.). (In the above description, each monocyclic 5- or 6-membered heterocyclic group portion includes a monocyclic 5- or 6- membered heterocyclic group containing 1 or 2 hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom, and examples of which include a pyridyl group, a pyrimidin- yl group, a thienyl group, etc.)
------Substituents of Group J ’
As substituents of Group B, the following substituents are mentioned: a lower alkyl group; a lower alkoxy-substituted lower alkyl group; a lower alkoxycarbonyl-substituted lower alkyl group; a hydroxy lower alkyl group; a carboxy lower alkyl group; . ~ a substituted or unsubstituted lower cycloalkyl group, a substituted or unsubstituted lower cycloalkyl-lower alkyl group, a substituted or unsubstituted phenyl group, a substituted or unsubstituted phenyl-lower alkyl group, a substituted or unsubstituted bicyclic hydrocarbon group, a substituted or unsubstituted monocyclic 5- or 6-membered heterocyclic group, a substituted or unsubstituted monocyclic 5- or 6-membered heterocyclic group-lower alkyl group. and a substituted or unsubstituted bicyclic heterocyclic group- lower alkyl group (substituents in the substituted lower cycloalkyl group portion, substituted phenyl group portion, substituted bicyclic hydrocarbon group portion, substituted monocyclic 5- or 6-membered heterocyclic group portion or substituted bicyclic heterocyclic group portion are not particularly limited, and examples of which include substituents in the substituents of Group C mentioned below.
A bicyclic hydrocarbon group portion includes a bicyclic hydrocarbon group having 9 to 11 carbon atoms, and examples of which include an indanyl group, etc.
Also, a monocyclic 5- or 6-membered heterocyclic group portion includes a monocyclic 5- or 6-membered heterocyclic group containing 1 or 2 hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom, and examples of which include a piperidyl group, a piperazinyl group, a morpholinyl group, a pyridyl group, a pyrimidinyl group, a pyrazinyl group, a pyridazinyl group, a pyrrolidinyl group, an imidazolidinyl" group, a pyrazolidinyl group, a pyrrolyl group, an imid- azolyl group, a pyrazolyl group, a thiazolyl group, a thiadiazolyl group, a thienyl group, etc.
Also, a bicyclic heterocyclic group portion includes a bicyclic heterocyclic group containing 1 to 3 hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom and comprising two 5- or 6-membered rings being fused, and examples of which include a benzodioxolanyl group, etc.) . ------Substituents of Group B' (more preferred substituents of Group B):----~~r--=--=--=----
As more preferred substituents of Group B, the following substituents are mentioned: a lower alkyl group (methyl group, ethyl group, isopropyl group, butyl group, etc.), a lower cycloalkyl group, a lower alkoxy-substituted lower alkyl group, a pyrimidinyl group, a thiazolyl group, a thiadiazolyl group.
As particularly preferred substituents of Group B, the following substituents are exemplified:
Tn case that R? is a di-substituted amino group, a lower alkyl group (methyl group, ethyl group, isopropyl group, butyl group, etc.), a lower cycloalkyl group and a lower alkoxy-substituted lower alkyl group; and in case that R? is a mono-substituted amino group, a pyrimidinyl group, a thiazolyl group and a thiadiazolyl group. ------Substituents of Group C:-----=-=-=---=-=-~-=-~
As substituents of Group C, the following substi- tuents are mentioned: a lower alkyl group; a hydroxy-lower alkyl group; a lower alkanoyl group; a lower cycloalkylcarbonyl group; a lower alkoxy group; a lower alkoxycarbonyl group; a lower alkyl- sulfonyl group; a di-lower alkyl-substituted carbamoyl group; a di-lower alkylamino-substituted lower alkanoyl group; and a substituted or unsubstituted phenyl group, a substituted or unsubstituted phenyl-O-, a substituted or unsubstituted phenyl-CO-, a substituted or unsubstituted phenyl-lower alkanoyl group, a substituted or unsubstituted phenyl-lower alkyl group, a substituted or unsubstituted phenyl-lower alkoxy group, a substituted or unsubstituted monocyclic 5- or 6-membered heterocyclic group, a substituted or unsubstituted monocyclic 5- or 6-membered heterocyclic group-0- (a pyridyloxy group, etc.), a substituted or unsubstituted monocyclic 5- or 6-membered heterocyclic group-CcO- (a pyridylcarbonyl group, etc.), and a substituted or unsubstituted monocyclic 5- or 6-membered heterocyclic group-substituted amino group (a pyridylamino group, etc.) {substituents in the substituted phenyl group portion or substituted monocyclic 5- or 6-membered heterocyclic group portion are not particularly limited, and examples of which include a halogen atom (Cl, F, Br, etc.), cyano group, nitro group, 0x0 group, a lower alkyl group, a lower alkoxy group, a lower alkanoyl group, and a lower alkoxycarbonyl group, etc.
Also, a monocyclic 5- or 6-membered heterocyclic group portion includes a monocyclic 5- or 6-membered heterocyclic group containing 1 or 2 hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom, and examples of which include a piperidyl group, a piperazinyl group, a morpholinyl group, a pyridyl group, a pyrimidinyl group, a pyrazinyl group, a pyridazinyl group, a pyrrolidinyl group, an imidazolidinyl group, a pyrazolidinyl group, a pyrrolyl group, an imid- azolyl group, a pyrazolyl group, a thiazolyl group, a thiadiazolyl group, a thienyl group, etc.)
In the objective compound [I] of the present invention, as R? when X is -N(R))- or -0-, a cyclic group which may be substituted may be mentioned as a preferred example.
Also, in the objective compound [I] of the present invention, as R? when X is -CO-, there may be mentioned (1) a monocyclic, bicyclic or tricyclic nitrogen-containing heterocyclic group which may be substituted or {2) an amino group which may be substituted, represented by the formula:
ZN . \ N— as preferred examples.
Also, in the objective compound [I] of the present invention, among the two kinds of cis-trans isomers based on a cyclohexyl ring in the structure [IT] as a standard plane, a trans-isomeric compound is more preferred from the viewpoint of obtaining higher DPPIV inhibitory activity.
That is, among the objective compound [I] of the present invention, a compound having the following partial struc- ture: & re Of or a pharmaceutically acceptable salt thereof is preferred.
In particular, for a compound in which the group X is -CO-, superiority of such trans isomer is remarkable.
As one compound group of the compounds of the present invention, among the compounds [I], those in which R? is (1) a cyclic group which may have 1 to 3 substituents which are the same or different and selected from the substi- tuents of Group A, where the cyclic group portion is (i) a monocyclic, bicyclic or tricyclic hydrocarbon group, or (ii) a monocyclic, bicyclic or tricyclic heterocyclic group, or (2) an amino group having 1 or 2 substituents which are the same or different and selected from the substituents of
Group B can be mentioned. (Compound Group 1)
Also, as other compound groups, among the compounds [I] or the above-mentioned Compound Group 1, the compounds in which R? is (1) a cyclic group which may be substituted, where the cyclic group portion is selected from the following (i) to (iv) : "(i) a monocyclic hydrocarbon group having 3 to 7 carbon atoms, (ii) a bicyclic hydrocarbon groups having 9 to 11 carbon atoms, (iii) a monocyclic heterocyclic group containing 1 or 2 hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom, and (iv) a bicyclic heterocyclic group containing 1 to 3 hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom and comprising two 5- to 7-membered rings being fused; or (2) a substituted amino group; can be mentioned (Compound Group 2).
Also, among the above-mentioned Compound Group 2, the compounds in which R? is (1) a cyclic group which may be substituted wherein the cyclic group portion is a group selected from phenyl group, cyclohexyl group, cyclopentyl group, cyclo- butyl group, cyclopropyl group, an indanyl group, an indenyl group, a naphthyl group, tetrahydronaphthyl, a pyrrolidinyl group, an imidazolidinyl group, a pyrazolidin- yl group, an oxolanyl group, a thiolanyl group, a pyrrolin- yl group, an imidazolinyl group, a pyrazolinyl group, a pyrrolyl group, an imidazolyl group, a pyrazolyl group, a triazolyl group, a tetrazolyl group, a furyl group, an oxazolyl group, an isoxazolyl group, an oxadiazolyl group, a thienyl group, a thiazolyl group, an isothiazolyl group, a thiadiazolyl group, a piperidyl group, a piperazinyl group, a morpholinyl group, a thiomorpholinyl group, a pyridyl group, a pyrimidinyl group, a pyrazinyl group, a pyridazinyl group, a pyranyl group, a tetrahydropyridyl group, a dihydropyridazinyl group, a perhydroazepinyl group, a perhydrothiazepinyl group, an indolinyl group, an iso- 5° indolinyl group, an indolyl group, an indazolyl group, an isoindolyl group, a benzimidazolyl group, a benzothiazolyl group, a benzoxazolyl group, a benzodioxolanyl group, a benzothienyl group, a benzofuryl group, a thienopyridyl group, a thiazolopyridyl group, a pyrrolopyridyl group, a dihydropyrrolopyridyl group, a quinolyl group, an iso- quinolyl group, a quinoxalinyl group, a quinazolinyl group, a phthalazinyl group, a cinnolinyl group, a chromanyl group, an isochromanyl group, a naphthyridinyl group and partially or completely saturated cyclic groups thereof; or (2) a substituted amino group can be mentioned (Compound
Group 3).
Also, in Compound Group 3, as more preferred compound group, the compounds in which R? is : (1) a cyclic group which may be substituted, where the cyclic group portion is a group selected from the group consisting of phenyl group, cyclohexyl group, a pyrrolidin- yl group, a tetrazolyl group, a furyl group, a thienyl group, a thiazolyl group, a piperidyl group, a piperazinyl group, a morpholinyl group, a thiomorpholinyl group, a pyridyl group, a pyrimidinyl group, a pyrazinyl group, a pyridazinyl group, a perhydroazepinyl group, an indolinyl group, an isoindolinyl group, a benzothienyl group, a thienopyridyl group, a pyrrolopyridyl group, a dihydro- pyrrolopyridyl group, a quinolyl group, an isoquinolyl group, a quinoxalinyl group and partially or completely saturated cyclic groups thereof; or (2) a substituted amino group can be mentioned (Compound
Group 4).
Also, in Compound Group 4, as more preferred compound group, the compounds in which R? is (1) a cyclic group which may be substituted wherein the cyclic group portion is a group selected from . a pyrrolidinyl group, a piperidyl group, a piperazinyl group, a morpholinyl group, a thiomorpholinyl group, a pyridyl group, a pyrimidinyl group, an indolinyl group, an isoindolinyl group, a pyrrolopyridyl group, a dihydro- pyrrolopyridyl group and partially or completely saturated’ cyclic groups thereof; or ) " (2) a substituted amino group can be mentioned (Compound
Group 5).
Also, among the compounds [I], as another more pre- ferred compound group, the compounds in which R? is (1) a cyclic group which may have 1 to 3 substituents, which are the same or different, selected from the substituents of Group A', where the cyclic group portion is selected from the group consisting of a pyrrolidinyl group, a piperidyl group, a piperazinyl group, a morpholinyl group, a thiomorpholinyl group. a pyridyl group, a pyrimidinyl group, an indolinyl group, an isoindolinyl group, a pyrrolopyridyl group, a dihydro- pyrrolopyridyl group and partially or completely saturated cyclic groups thereof; or (2) an amino group substituted by 1 or 2 substituents, which are the same or different, selected from the substi- tuents of Group B' can be mentioned. (Compound Group 6)
Also, among the compounds [I], or among each of the . above-mentioned Compound Groups 1, 2, 3, 4, 5 and 6, a compound group in which, when X is -N(R}) - or -0-, R? is a cyclic group which may be substituted can be mentioned. (Compound Group 7)
Also, among the compounds [I], or among each of the above-mentioned Compound Groups 1, 2, 3, 4, 5 and 6, a group of compounds in which, when X is -CO-, R? is (1) a monocyclic, bicyclic or tricyclic nitrogen-containing heterocyclic group which may be substituted or (2) an amino group which may be substituted, represented by the formula:
NT can be mentioned. (Compound Group 8)
Also, among the compounds [I] or the above-mentioned } Compound Groups 1, 2, 3, 4, 5, 6, 7 or 8, as more preferred compound groups, a compound group in which X is -CO- or -0- and A is -CHj-; a compound group in which X is -CO- or -O-, A is -CH;- and
R! is hydrogen atom; a compound group in which X is -CO-, A is -CH;- and R' is hydrogen atom; a compound group in which X is -CO-, A is -CH;-, R! is hydrogen atom and R? is a cyclic group which may be substi- tuted; a compound group in which X is -CO-, A is -CHz-, R' is hydrogen atom and R? is a substituted amino group; a compound group in which X is -CO- or -O- and A is -S-; - a group of compounds in which X is -CO- or -0-, A is -S- and R' is hydrogen atom; a compound group in which X is -CO-, A is -S- and R! is hydrogen atom; a compound group in which X is -CO-, A is -S-, R! is hydro- gen atom and R? is a cyclic group which may be substituted; a compound group in which X is -CcO-, A is -S-, R' is hydro- gen atom and R? is a substituted amino group, etc. may be mentioned.
Also, in each of the above-mentioned compound groups, . as a more preferred compound group, a compound group having the following partial structure:
R1 —xnd Hp can be mentioned.
Also, among the compounds [I], the following com- pounds can be mentioned as examples of preferred compounds;
(S)-2-cyanoc-1-[trans-4-(5-nitro-2-pyridylamino) - cyclohexylamino]acetylpyrrolidine; (8S) -2-cyano-1-[trans-4-(5-cyano-2-pyridyloxy) - cyclohexylaminolacetylpyrrolidine; (S) -2-cyano-1-[trans-4- (dimethylaminocarhonyl) - cyclohexylamino]acetylpyrrolidine; (S) -2-cyano-1-[trans-4- (morpholinocarbonyl)cyclo- hexylamino]acetylpyrrolidine; (S)-2-cyano-1-[trans-4-{5-bromo-2-pyrimidinyloxy) - cyclohexylamino] acetylpyrrolidine; (S)-2-cyano-1-[trans-4- (5-pyrimidinylaminoccarbonyl) - cyclohexylamino] acetylpyrrolidine; (S) -2-cyano-1-[trans-4-{(N-ethyl-N-methoxyethylamino- carbonyl) cyclohexylaminol]acetylpyrrolidine; (S)-2-cyano-1-[trans-4- (N-ethyl-N-isopropylamino- carbonyl) cyclohexylaminolacetylpyrrolidine; (Ss) -2-cyano-1-[trans-4- (N-methyl-N-butylamino- carbonyl) cyclohexylamino]acetylpyrrolidine; (S) -2-cyano-1-[trans-4-[(S)-2-methoxymethylpyrroli- din-1l-ylcarbonyl] cyclohexylamino]acetylpyrrolidine; (S)-2-cyano-1-[trans-4-(3-carbamoylpiperidinocarbon- vl) cyclohexylamino]acetylpyrrolidine; (S) -2-cyano-1-[trans-4-{(3-nitro-2-pyridylamino)cyclo- hexylamino]acetylpyrrolidine; (S) -2-cyano-1-[trans-4-(4-acetylpiperazin-1-ylcarbon- vl) cyclohexylamino]acetylpyrrolidine; } (S) -2-cyano-1- [trans-4- (2-isoindolinylcarbonyl)cyclo- hexylamino] acetylpyrrolidine; (S) -2-cyano-1-[trans-4-[4-(3-pyridylcarbonyl)pipera- zin-1l-ylcarbonyl]cyclohexylamino]acetylpyrrolidine; (8) -2-cyano-1-{trans-4-[4-(3-thenoyl)piperazin-1-yl- carbonyl] cyclohexylamino}lacetylpyrrolidine; (8) -2-cyano-1-{trans-4-{4-{(4-chlorophenyl)piperazin- 1-ylcarbonyl]cyclohexylaminolacetylpyrrolidine; (§) -2-cyano-1-[trans-4-{cis-2,6-dimethylmorpholino- carbonyl) cyclochexylamino]acetylpyrrolidine;
(S)-2-cyano-1-[trans-4-(5-nitro-2-isoindolinyl- carbonyl) cyclohexylaminolacetylpyrrolidine; (S)-2-cyano-1l-{trans-4-{(piperidinocarbonyl)cyclo- hexylamino]acetylpyrrolidine; (S)-2-cyano-1-({trans-4-(4-carbamoylpiperidinocarbon- yl) cyclohexylamino] acetylpyrrolidine; Co (S)-2-cyano-1-[trans-4-(1l-pyrrolidinylcarbonyl) - . cyclohexylamino] acetylpyrrolidine; N (S)-2-cyano-1-[trans-4-(4-cyclopropylcarbonyl- priperazin-1-ylcarbonyl)cyclohexylamino]lacetylpyrrolidine; (S)-2-cyano-1-[trans-4- (4 -propionylpiperazin-1-yl- carbonyl) cyclohexylamino]acetylpyrrolidine; (S)-2-cyano-1-[trans-4-(1l-indolinylcarbonyl)cyclo- hexylamino]acetylpyrrolidine; (S)-2-cyano-1-[trans-4-(2,3-dihydro-1H-pyrrolo(3,4- blpyridin-2-ylcarbonyl)cyclohexylamino]acetylpyrrolidine; (S)-2-cyano-1-[trans-4-[4-(2-pyrimidinyloxy) - piperidinocarbonyll cyclohexylaminolacetylpyrrolidine; (S)-2-cyano-1-{trans-4-[4-(5-bromo-2-pyrimidinyloxy) - piperidinocarbonyllcyclohexylaminolacetylpyrrolidine; (S)-2-cyano-1-[trans-4-{(cis-3,5-dimethyl-4-benzyl- piperazin-1-ylcarbonyl)cyclohexylamino] acetylpyrrolidine; (S)-2-cyano-1-[trans-4-(4-cyclohexylcarbonylamino- piperidinocarbonyl) cyclohexylamino] acetylpyrrolidine; (S)-2-cyano-1-{trans-4-[4- (N-phenylcarbamoyl) - piperazin-l-ylcarbonyl]lcyclohexylamino}lacetylpyrrolidine; } (S) -2-cyano-1-[trans-4- (4-ethoxycarbonylpiperazin-1- ylcarbonyl) cyclohexylaminol acetylpyrrolidine; (S)-2-cyano-1-{trans-4-[4- (2-thienyl)piperidino- carbonyl] cyclohexylamino}acetylpyrrolidine; (S)-2-cyano-1-[trans-4-(1,1-dioxoperhydro-1,4-thia- zin-4-ylcarbonyl)cyclohexylamino]acetylpyrrolidine; (R) -4-cyano-3-[trans-4-(5-nitro-2-pyridylamino)cyclo- hexylamino]acetylthiazolidine; (R) -4-cyano-3-[trans-4-(5-cyano-2-pyridyloxy)cyclo- hexylamino]acetylthiazolidine;
(R) -4-cyano-3- [trans-4- (dimethylaminocarbonyl)cyclo- hexylamino]acetylthiazolidine; (R) -4-cyano-3- [trans-4- (2-isoindolinylcarbonyl)cyclo- hexylamino]acetylthiazolidine; (R) -4-cyano-3- [trans-4- {(morpholinocarbonyl)cyclo- hexylamino]acetylthiazolidine; and (R) -4-cyano-3- [trans-4- (pyrrolidinylcarbonyl)cyclo- hexylaminol]acetylthiazolidine.
The objective compound [I] or a pharmaceutically acceptable salt thereof of the present invention has superior inhibitory action on the enzyme activity of DPPIV.
They have superior inhibitory action especially on human
DPPIV. In addition, they also exhibit high selectivity with respect to DPPIV (namely, type IV dipeptidylpeptidase) in various serine proteases (e.g., plasmin, thrombin, prolylendopeptidase, trypsin and dipeptidylpeptidase II). :
Also, the objective compound [I] or a pharmaceuti- cally acceptable salt thereof of the present invention improves insulin secretion response to oral glucose loading by means of its DPPIV inhibitory action.
Thus, the objective compound [I] or a pharmaceuti- cally acceptable salt thereof of the present invention is useful as prophylactic or therapeutic agents for diseases relating to DPPIV (diseases mediated by DPPIV), that is, diseases which is expected to be alleviated by inhibiting
DPPIV enzyme activity.
Examples of such diseases include diabetes (e.g., -
N : type 1 diabetes and type 2 diabetes), hyperglycemia (such as postprandial hyperglycemia), hyperinsulinemia, diabetes complications (such as renal disorder and neurological : disorder), obesity, overeating, lipid metabolism disorder (such as hyperlipemia including hypertriglyceridemia and others), autoimmune diseases (such as arthritis and rheumatoid arthritis), osteoporosis, acquired immunodefi- ciency syndrome (AIDS) and rejection of transplanted organs and tissues.
The objective compound [I] or a pharmaceutically acceptable salt thereof of the present invention is parti- cularly useful as a prophylactic or therapeutic agent of diabetes (and particularly type 2 diabetes).
Also, the compound of the present invention has low toxicity, and thus, has a high degree of safety when used as a pharmaceutical compound. Also, it also demonstrates superior pharmacokinetic characteristics [including bio- availability, in vitro metabolic stability (stability in human liver homogenates), P450 inhibitory action, protein binding capabilities, etc.].
The DPPIV inhibitory action of the compound of the present invention as well as its pharmaceutical efficacy (including anti-hyperglycemia effect and the effect of improving insulin secretion response to glucose loading) based on that action can be confirmed by known methods or methods equivalent to those methods (W098/19998; W000/ 34241; Holst, et al., Diabetes, Vol. 47, pp. 1663-1670, 1998; Augustyns, et al., Current Medicinal Chemistry, Vol. 6, pp. 311-327, 1999; Meester, et al., Immunol. Today, Vol. 20, pp. 367-375, 1999; and, Fleicher, et al., Immunol.
Today, Vol. 15, pp. 180-184, 1994).
The objective compound [I] of the present invention can be used for a pharmaceutical use either in a free form or in a form of a pharmaceutically acceptable salt.
Examples of the pharmaceutically acceptable salt of the compound [I] include an inorganic acid salt such as hydro- : chloride, sulfate, phosphate or hydrobromide, and an organic acid salt such as acetate, fumarate, oxalate, : citrate, methanesulfonate, benzenesulfonate, tosylate or maleate, etc. In addition, in case that a compound has a substituent (s) such as carboxyl group, a salt with a base (for example, an alkali metal salt such as a sodium salt, a potassium salt, etc., or an alkaline earth metal salt such as a calcium salt and the like) may be mentioned.
The objective compound [I] or a pharmaceutically acceptable salt thereof of the present invention includes its internal salt, an adduct, a solvate and a hydrate.
The objective compound [I] or a pharmaceutically acceptable salt thereof of the present invention can be administered orally or parenterally and used as commonly ., used pharmaceutical preparations such as a tablet, granule, capsule, powder, injection solution and inhalant. For example, the compound of the present invention can be used with an excipient or a diluent acceptable for general pharmaceuticals such as a binder, disintegrator, extender, filler and lubricant, to form a preparation according to the usual method.
The administration dose of the objective compound [I] or a pharmaceutically acceptable salt thereof of the present invention may vary depending on the administration method, age, weight and condition of a patient, and it is generally about 0.01 to 300 mg/kg, particularly preferably about 0.1 to 30 mg/kg per day.
The objective compound [I] of the present invention can be prepared according to the following (Process A) and (Process B), but it is not limited to these processes. (Process A)
The objective compound [I] of the present invention can be prepared by reacting a compound represented by the formula [II]:
Z'—CHp-CO-N" DA )— [11]
CN - wherein 2! represents a reactive residue and A has the same meaning as defined above, with a compound represented by the formula [III]:
R! rex Yon, [111]
wherein R!, R? and X have the same meanings as defined above, or a salt thereof, and optionally, by making the product into a pharmaceutically acceptable salt.
As examples of the salt of the compound [III], a salt with an inorganic acid such as hydrochloride and sulfate, : or a salt with an inorganic base such as an alkali metal salt and an alkaline earth metal salt can be used.
As the reactive residue of z', commonly used reactive residues such as a halogen atom, a lower alkylsulfonyloxy group and an arylsulfonyloxy group can be used, among which the halogen atom is particularly preferred.
The reaction of the compound [II] with the compound [III] or the salt thereof can be carried out in a suitable solvent or without solvent in the presence or absence of an acid acceptor.
As the solvent, any solvents may be suitable as long as it does not adversely affect to the reaction, and, for example, acetonitrile, methanol, ethanol, isopropyl alcohol, propyl alcohol, acetone, dimethylformamide, dimethyl sulfoxide, tetrahydrofuran, ether, dioxane, ethyl acetate, toluene, methylene chloride, dichloroethane, chloroform or a mixed solvent of these solvents can be suitably used.
This reaction suitably proceeds at 0 to 120°C, par- ticularly at room temperature to 80°C.
As the acid acceptor, an inorganic base (for example, alkali metal hydride such as sodium hydride, alkali metal carbonate such as sodium carbonate and potassium carbonate, ) " alkali metal alkoxide such as sodium methoxide, alkali metal such as sodium, and alkali metal hydroxide such as sodium hydroxide and potassium hydroxide, etc.) or an organic base (for example, triethylamine, diisopropyl- ethylamine, N-methylmorpholine, pyridine, dimethylaniline, dimethylaminopyridine, etc.) can be suitably used. (Process B)
In addition, among the objective compound [I] of the present invention, the compound represented by the formula [I-a]:
R! -co~ Ynr-crp-co—y a T-al
CN wherein R?! represents (1) a monocyclic, bicyclic or tricyclic nitrogen-containing heterocyclic group which may be substituted or (2) an amino group which may be substituted, and represented by the formula: t N— 4 and R! and A have the same meanings as defined above, can be prepared by reacting a compound represented by the formula [IV]:
R
VN
HOOC N—CH2-CO-N" “A Iv]
R4
CN wherein R! represents a protective group for an amino group, and R! and A have the same meanings as defined above, or a salt thereof with the compound represented by the formula [V]: : R2!-H C- : or a salt thereof to obtain a compound represented by the formula [VI]:
R? 21 EN
R co Yon—onz-c0— A [VI]
La \—/
CN wherein R', R!, R?! and A have the same meanings as defined above, or a salt thereof, and by removing the protective group for the amino group (RY) from the product, and optionally, by . 5 making the product into a pharmaceutically acceptable salt.
As examples of salts of the compounds [IV] to [VI], a salt with an inorganic acid such as hydrochloride and sulfate, or a salt with an inorganic base such as an alkali metal salt and an alkaline earth metal salt can be used.
As the protective group for the amino group of RY, any of the commonly used protective groups for the amino group such as t-butoxycarbonyl group, benzyloxycarbonyl group, trifluoroacetyl group, chloroacetyl group, 9- fluorenylmethyloxycarbonyl group, etc. can be suitably used.
The reaction of the compound [IV] or a salt thereof with the compound [V] or a salt thereof can be carried out in a suitable solvent or without solvent in the presence or absence of a condensing agent.
As the solvent, any solvents may be suitable as long as it does not adversely affect to the reaction, and, for example, acetonitrile, methanol, ethanol, isopropyl alcohol, propyl alcohol, acetone, dimethylformamide, tetrahydrofuran, ether, dioxane, ethyl acetate, toluene, methylene chloride, dichloroethane, chloroform or a mixed solvent of these solvents can be suitably used. oo This reaction suitably proceeds at 0 to 120°C, parti- cularly at room temperature to 80°C.
For the condensing agent, O-benzotriazol-1-yl-
N,N,N',N'-tetramethyluroniumhexafluorophosphate, DCC {dicyclohexylcarbodiimide), EDC (l-ethyl-3-(3-dimethyl- aminopropyl) carbodiimide), chloroformates (for example, ethyl chloroformate and isobutyl chloroformate) and carbonyldiimidazole can be suitably used.
Also, for promoting the reaction, additives such as base (sodium carbonate, sodium hydrogencarbonate, tri- ethylamine, pyridine, 4-dimethylaminopyridine, diisopropyl-
ethylamine, 1,8-diazabicyclo(5.4.0]Jundec-7-ene, etc.), 1- } hydroxybenzotriazole, 1l-hydroxysuccinimide, etc. can be added to the above condensing agents.
The subsequent removal of the protective group (RY) for the amino group of the compound [VI] can be carried out according to the conventional method, and it can be carried out, for example, in a suitable solvent or without solvent by an acid treatment, base treatment or catalytic reduction.
As the solvent, any solvents may be suitable as long as it does not adversely affect to the reaction, and, for example, methanol, ethanol, isopropyl alcohol, propyl alcohol, dioxane, methylene chloride, chloroform, dichloro- ethane, ether, tetrahydrofuran, ethyl acetate, toluene or a mixed solvent of these solvents can be suitably used.
This reaction suitably proceeds at -78 to 80°C, particularly at 0°C to room temperature.
As the acid, an inorganic acid such as hydrochloric acid, sulfuric acid, etc., and an organic acid such as acetic acid, trifluoroacetic acid, methanesulfonic acid, p- toluenesulfonic acid, etc. can be suitably used.
As the base, an inorganic base (for example, alkali metal hydride such as sodium hydride, etc., alkali metal carbonate such as sodium carbonate, potassium carbonate, etc., alkali metal alkoxide such as sodium methoxide, etc., alkali metal such as sodium, etc., and alkali metal } hydroxide such as sodium hydroxide, potassium hydroxide, etc.) or an organic base (for example, triethylamine, diisopropylethylamine, morpholine, N-methylmorpholine, pyridine, piperidine, dimethylaniline, dimethylamino- pyridine, etc.) can be suitably used.
The catalytic reduction can be carried out by suit- ably using palladium-carbon, palladium hydroxide-carbon, platinum oxide or Raney nickel under hydrogen atmosphere.
The starting material [II] of the present invention can be prepared, for example, according to the method described in International Patent Publications Nos. WO
: 98/19998, WO 00/34241, Reference Examples (Reference
Example 1 or 2) mentioned below and the like.
For example, the compound [II] can be obtained by reacting a compound represented by the formula [10]:
HN OA . / [10] i CONH; wherein A has the same meaning as defined above, with a compound represented by the formula [11]: z?-CH,Cc0-2? [11] wherein Zz? and 2’ represent reactive residues which may be the same or different, in the presence of an acid acceptor (for example, triethyl- amine) to obtain a compound represented by the formula
[12]: 72-CHp-CO-N" A
VJ [12]
CONH, wherein Z2 and A have the same meanings as defined above, and treating the product with a dehydrating agent (for example, phosphorous oxychloride, trifluoroacetic anhydride, etc.) according to the conventional method.
As the reactive residue of Zz? or Zz’, the same reactive residue commonly used as in the above 7' can be suitably used.
The starting material [III] can be prepared, for example, by the same method as described in Reference
Examples (Reference Examples 3 to 14) mentioned below.
For example, the compound [III] in which X is -N(R?)- or -0O- can be prepared by reacting a compound represented by the formula [13]:
R - fw wherein Vv! represents -NH(R®) - or hydroxy group, and
R' and R® have the same meanings as defined above, an amino group-protected material thereof or a salt thereof with a compound represented by the formula [14]:
R%-z* [14] wherein 2! represents a reactive residue and R? has the same meaning as defined above, in the presence or absence of an acid acceptor (for example, an organic base such as triethylamine, diisopropylethyl- amine, etc., and an inorganic base such as sodium hydride, potassium carbonate, etc.), and, if necessary, by removing the protective group for the amino group according to the conventional method.
As the protective group for the amino group, any of the same protective groups commonly used as in the above R* can be suitably used.
As the reactive residue of z%, the same reactive residues commonly used as in the above z! can be suitably used.
For example, the compound [III] in which X is -CO- and R? is a group represented by the formula: . ZN { N—
N._..” . . : can be produced by reacting a compound represented by the formula [15]:
R! wherein V? represents -COOH and R! has the same meaning as defined above,
an amino group-protected material thereof or a salt thereof with a compound represented by the formula [16]:
R**-H [16] wherein R?? represents (1) a monocyclic, bicyclic or tricyclic nitrogen-containing heterocyclic group which may be substituted or (2) an amino group which may be substituted, represented by the formula: as \_/ and forms a cyclic or straight amine together with hydrogen atom, or a salt thereof, in the presence of a condensing agent {({l-ethyl-3-(3-dimethylaminopropyl) carbodiimide, etc.) and, if necessary, by removing the protective group for the amino group according to the conventional method.
Or else, the compound [III] in which X is -CO- can be obtained by reacting a compound represented by the formula
[17]:
R! zoe Yon, [17] wherein Z° represents a reactive residue and R! has the same meaning as defined above, an amino group-protected material thereof or a salt thereof with a compound represented by the formula [18]:
R*-sSn(R®), [18] wherein R® represents a lower alkyl group and R? has the same meaning as defined above, in the presence of a palladium catalyst (for example, dichlorobis{triphenylphosphine)palladium, etc.).
As the protective group for the amino group, any of the same protective groups commonly used as in the above
R* can be suitably used. Also, as the reactive residue of 73, the same reactive residues commonly used as in the above 2! can be suitably used.
Or else, the compound [III] in which X is -N(R’)- can be prepared by reacting the compound represented by the formula [19]: a a. R' o=( Yorn, [19] wherein R! has the same meaning as defined above, an amino group-protected material thereof or a salt thereof with the compound represented by the formula [20]:
R*-V’ [20] wherein V® represents -N(R*)H and R? has the same meaning as defined above, in the presence of a reducing agent (sodium triacetoxyboro- hydride, etc.) and, if necessary, by removing the protec- tive group for the amino group according to the conven- tional method.
As the protective group for the amino group, any of the same protective groups commonly used as in the above R* can be suitably used.
The starting materials [10] to [20] can be prepared according to known methods or in the same manner as described in Reference Examples mentioned below.
In order to obtain a trans form of the starting material [III] taking a cyclohexane ring as a standard plane, each trans form of the starting cyclohexane compounds (the compounds [13], [15], [17], etc.) may be used. -
Also, the starting material [IV] can be prepared, for example, in the same manner as in the process described in
Example (Example 3-1, (1) to (3)) mentioned below or in accordance with these processes, as shown in the following figure. (In the figure, 7 represents a reactive residue,
R! represents a protective group for an amino group and other symbols have the same meanings as defined above.)
As the reactive residue of Zz°, the same reactive residues commonly used as in the above Z' can be suitably used. 0]
R! Ay
NH, R' bo; R' R* 0
HAC Ne HOF Sop NC Some
CO LL ° a J, 0 (1) HC X 2) H.C? NC
O .
R i Q
Fe 4
HO NC
Oo [Compound IV]
The compound [I] of the present invention or its starting material prepared according to the above is iso- lated in a free form or as a salt thereof, and purified.
The salt can be prepared by subjecting to the salt-forming treatment conventionally used.
Isolation and purification can be carried out by applying the usual chemical operations such as extraction, concentration, crystallization, filtration, recrystalliza- tion, various kinds of chromatographies and the like.
In the compound of the present invention, optical isomers such as racemic isomers, optically active isomers, diastereomers, etc. can be present alone or as mixtures thereof. A stereochemically pure isomer can be derived by using a stereochemically pure starting material or by ’ separating an optical isomer according to the general separation process for racemic resolution. Also, dias- tereomeric mixtures can be separated according to the conventional method, for example, fractional crystalliza- tion or by chromatography.
The present invention will be described in detail by referring to the following Examples but these Examples do not intend to limit the present invention.
Example la-1
A acetonitrile-methanol solution containing 100 mg of (S) -1-bromoacetyl-2-cyanopyrrolidine (Reference Example 1 mentioned below) and 327 mg of N-(5-nitro-2-pyridyl) -trans- 1,4-cyclohexanediamine (Reference Example 3-1 mentioned below) was stirred at room temperature for 15 hours. Water was added to the reaction mixture and the mixture was extracted with chloroform. After the extract was dried io over sodium sulfate, the solvent was removed under reduced pressure. The residue was purified by dicl column chromatography (solvent: 0 to 10% methanol-chloroform) to obtain an oily product. The oily product was dissolved in 0.5 ml of ethyl acetate-0.5 ml of chloroform, and then, 1.0 ml of 2N hydrochloric acid-ether and 2 ml of ether were successively added thereto. Precipitates were collected by filtration and washed with ether to obtain (S)-2-cyano-1- [trans-4- (5-nitro-2-pyridylamino)cyclohexylamino]acetyl- pyrrolidine dihydrochloride (Example la-1 in Table 1a).
Examples la-2 to 1d-152
Using (S) -1-bromoacetyl-2-cyanopyrrolidine and corresponding starting materials, they were treated in the same manner as in Example la-1, compounds of Tables la to 1d shown below (Examples la-2 to la-89, 1b-1 to 1b-71, 1lc-1 to 1c-52 and 1d-1 to 152) were obtained. Incidentally, the corresponding starting materials were obtained by the similar method as described in Reference Examples mentioned below, by known methods or by a method in combination of - these methods.
Provided that the compound of Example 14-77 was obtained by using trans-4-(l-piperazinylcarbonyl)cyclo- hexylamine as a starting material.
Also, the compound of Example 1c-39 (namely, (8)-2- cyano-1-{trans-4-[(N-carboxymethyl-N-methylamino) carbonyl] - cyclohexylamino}lacetylpyrrolidine hydrochloride) was obtained by treating the compound of Example 1c-38 (namely,
(S)-2-cyano-1-{trans-4-[(N-tert-butoxycarbonylmethyl-N- methylamino)carbonyllcyclohexylaminolacetylpyrrolidine) with trifluoroacetic acid, followed by treating with hydrochloric acid.
Also, the compound of the Example 1d-14 (namely, (S)- 2-cyano-1-[trans-4- (l-piperazinylcarbonyl)cyclohexylamino] - acetylpyrrolidine-dihydrochloride) was obtained by treating a free form of the compound of Example 14-70 ((S)-2-cyano- 1- [trans-4- (4-benzyloxycarbonyl-1-piperazinylcarbon- yl) cyclohexylamino] acetylpyrrolidine) with trimethylsilyl iodide.
Examples 2-1 and 2-2 (1) A mixture of 600 mg of 4-tert-butoxycarbonylamino-4- methylcyclohexanone (the compound of Reference Example 6-1, (3)), 783 mg of sodium triacetoxyborohydride, 343 mg of 3- cyancaniline, 159 mg of acetic acid and 6 ml of dichloro- ethane was stirred at room temperature for 16 hours. The mixture was diluted with an aqueous saturated sodium hydro- gencarbonate solution and then extracted with chloroform.
The extract was dried over anhydrous sodium sulfate and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (solvent: hexane-ethyl acetate (4:1) to (1:1)) to obtain 304 mg of N- tert-butoxycarbonyl-1l-methyl-c-4- (3-cyano-phenylamino) -r-1- cyclohexylamine and 292 mg of N-tert-butoxycarbonyl-1- methyl-t-4- (3-cyano-phenylamino) -r-1-cyclohexylamine. . . (2) 243 mg of N-tert-butoxycarbonyl-1l-methyl-c-4-(3-cyano- phenylamino) -r-1-cyclohexylamine obtained in the above (1) was stirred in a mixture of 2 ml of 4N hydrochloric acid/ dioxane and 2 ml of ethanol at room temperature for 15 hours.
After the reaction mixture was concentrated, to the residue were added 320 mg of (S)-l-bromoacetyl-2-cyano- pyrrolidine, 0.6 ml of triethylamine, 3.5 ml of aceto- nitrile and 1 ml of methanol and the mixture was stirred at room temperature for 15 hours. The mixture was diluted with an aqueous saturated sodium hydrogencarbonate solution and extracted with chloroform. The extract was dried over anhydrous sodium sulfate and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (solvent: chloroform-methanol (50:1)) to obtain 154 mg of the compound, which was then treated with hydrochloric acid to yield (S)-2-cyano-1l-[l-methyl-c- 4-(3-cyano-phenylamino) -r-1-cyclohexylamino]acetylpyrroli- dine-dihydrochloride (Table 2: Example 2-1). (3) Using N-tert-butoxycarbonyl-1l-methyl-t-4-(3-cyano- phenylamino) -r-1-cyclohexylamine obtained in the above (1), it was treated in the same manner as in (2), (S8)-2-cyano-1l- [1-methyl-c-4- (3-cyano-phenylamino) -r-1-cyclohexylamino} - acetylpyrrolidine-dihydrochloride (Example 2-2 in Table 2) was obtained.
Examples 2-3 to 2-8
Using corresponding starting materials, they were treated in the same manner as in Examples 2-1 to 2-2, compounds of Examples 2-3 to 2-8 shown in Table 2 were obtained.
Example 3-1
PA
ST OH O Boe © eo J HT ag = Cr o) m HC? r @ ae NC © 0 Boc O
Clk She Chr HO oD
N ha NC ~~ ™ NC :
Oo @ o
Example 3-1 (1) In water was dissolved 5.0 g of trans-4-ethoxycarbonyl - cyclohexylamine dihydrochloride, and after the solution was made basic by adding potassium carbonate, the solution was extracted with chloroform. The extract was washed with brine, dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure.
A mixture of the residue, 5.1 g of p-toluensulfonic acid monohydrate and 50 ml of allyl alcohol was refluxed for 48 hours.
The reaction mixture was concentrated, and then, diluted with chloroform.
The chloroform solution was washed with an aqueous potassium carbonate solution, water and brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
The residue was purified by silica gel flash column chromatography (solvent: chloroform-methanol-
aqueous ammonia (500:10:1)) to obtain 3.29 g of trans-4-(2- propenyloxycarbonyl) cyclohexylamine.
(2) A mixture of 507 mg of the compound obtained in the above (1), 400 mg of (S)-1-bromoacetyl-2-cyanopyrrolidine, 714 mg of N,N-diisopropylethylamine and 4 ml of aceto-
nitrile was stirred at 50°C for 12 hours.
After cooling to room temperature, 476 mg of N,N-diisopropylethylamine, followed by 4 ml of acetonitrile solution containing 803 mg of di-tert-butyldicarbonate were added to the reaction mixture, and the mixture was stirred at room temperature for 3 hours.
After the reaction mixture was concentrated, the concentrate was diluted with ethyl acetate.
The ethyl acetate solution was washed with an aqueous 10% citric acid sclution, water and brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
The residue was purified by silica gel flash chromatography (solvent: chloroform-methanol (100:1)) to obtain 658 mg of (S) -2-cyano-1- [N-tert-butoxycarbonyl-trans-4- (2-propenyl- oxycarbonyl)cyclohexylaminolacetylpyrrolidine.
: (3) A mixture of 600 mg of the compound obtained in the above (2), 165 mg of tetrakis(triphenylphosphine)palladium, 271 mg of ammonium formate and 6 ml of dioxane was stirred at 50°C for 1 hour.
After cooling, the reaction mixture was poured into water and extracted with chloroform.
The extract was washed with brine, dried over anhydrous sodium sulfate, and then, the solvent was removed under reduced pressure.
The residue was purified by silica gel flash chromatography (solvent: chloroform-methanol (50:1)) to obtain 394 mg of (S)-2-cyano-1-(N-tert-butoxycarbonyl- trans-4-carboxycyclohexylamino)acetylpyrrolidine. (4) A solution of 2 ml N,N-dimethylformamide containing 150 mg of the compound obtained in the above (3), 64 mg of 2- aminomethylpyridine, 114 mg of l-ethyl-3-(3-dimethylamino- _ propyl) -carbodiimide and 80 mg of 1-hydroxybenzotriazole oo was stirred at room temperature for 24 hours. An agueous saturated sodium hydrogencarbonate solution was added to the reaction mixture and the mixture was extracted with chloroform. The extract was washed with brine and dried over anhydrous sodium sulfate and the solvent was removed under reduced pressure. The residue was dissolved in 3 ml of acetonitrile, and 1 ml of an acetonitrile solution of 118 mg of trimethylsilyl iodide was added dropwise to the solution under ice-cooling, and the mixture was stirred at room temperature for 30 minutes. To the reaction mixture were added methanol and water, and after stirring for a while, the mixture was neutralized with an aqueous saturated sodium hydrogencarbonate solution, and then, extracted with chloroform. The extract was washed with an aqueous saturated sodium hydrogencarbonate solution, water and brine, dried over anhydrous sodium sulfate, and then, the solvent was removed under reduced pressure. The residue was purified by diol chromatography (solvent: chloroform) to obtain an oily product. The oily product was dissolved in 1 ml of ethyl acetate, and then, 0.5 ml of iN hydrochloric acid-ether followed by 2 ml of ether were added thereto, and precipitates were washed with ether to obtain 106 mg of (S)-2-cyano-1-[trans-4-(2- ) pyridylmethylaminocarbonyl)cyclo- hexylamino] acetylpyrrolidine-dihydrochloride (Example 3-1 in Table 3).
Examples 3-2 to 3-12
The compounds of Examples 3-2 to 3-12 in Table 3 were obtained in the same manner as in Example 3-1 (4), using
(S) -2-cyano-1- (N-tert-butoxycarbonyl-trans-4-carboxycyclo- hexylamino)acetylpyrrolidine (the compound of the above
Example 3-1 (3)) and the corresponding starting materials.
Examples 4-1 to 4-32
A solution of 2 ml of acetonitrile-1 ml of methanol containing 100 mg of (R) -3-chloroacetyl-4-cyanothiazolidine (the compound of Reference Example 2 mentioned below) and 372 mg of N-(5-nitro-2-pyridyl)-trans-1,4-cyclohexane- diamine was stirred at room temperature for 15 hours.
Water was added to the reaction mixture and the mixture was extracted with chloroform. After the extract was dried over anhydrous sodium sulfate, the solvent was removed under reduced pressure. The residue was purified by diol column chromatography (solvent: 0 to 5% methancl-chloro- form) to obtain an oily product. The oily product was dissolved in 0.5 ml of ethyl acetate-0.5 ml of chloroform, and 1.0 ml of 2N hydrochloric acid-ether was added thereto, followed by 2 ml of ether. Precipitates were collected by filtration and washed with ether to obtain 173 mg of (R)-4- cyano-3-[trans-4-(5-nitro-2-pyridylamino)cyclohexylamino] - acetylthiazolidine dihydrochloride (Example 4-1 in Table 4).
Also, the compounds of Examples 4-2 to 4-32 in Table 4 were obtained in the same manner as mentioned above, using the corresponding starting materials.
Reference Example 1
N According to the process described in the literature (Ww0 $8/19998), (S) -1-bromoacetyl-2-cyanopyrrolidine was obtained by reacting L-prolineamide (commercially available product) and bromoacetyl bromide, followed by dehydration.
Reference Example 2
L-thioprolineamide hydrochloride was synthesized according to the process described in the literature (Ashworth et. al., Bioorg. Med. Chem. Lett., Vol. 6, pp. 2745-2748, 1996). 2.36 ml of chloroacetyl chloride was added to a solution of 150 ml of dichloromethane containing 5.00 g of L-thioprolineamide hydrochloride thus obtained and 8.67 ml of triethylamine under ice-cooling, and the mixture was stirred at the same temperature for 1 hour. To the reaction mixture was added a dichloromethane solution - containing 4.8 ml of pyridine and 8.4 ml of trifluoroacetic anhydride, and the mixture was further stirred at room temperature for 1 hour. The reaction mixture was washed with an aqueous 10% HCl solution and water, dried over anhydrous magnesium sulfate, filtered and concentrated
Co "uhder reduced pressure, and subsequently, the residue was crystallized from ether to obtain 4.82 g of (R)-3-chloro- acetyl-4-cyanothiazolidine as yellow-brownish crystals.
Reference Examples 3-1 to 3-40
A solution of 5-nitro-2-chloropyridine (2.50 g) and trans-1,4-cyclohexanediamine (5.40 g) in ethanol (15 ml) - tetrahydrofuran (10 ml) was stirred at room temperature for 5 days. The precipitates were removed by filtration and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent: chloroform-methanol-concentrated aqueous ammonia (20:4:1)) and crystallized from ethyl acetate to obtain N- (5-nitro-2-pyridyl) -trans-1,4-cyclohexanediamine (Reference
Example 3-1 in Table 5).
Also, the compounds of Examples 3-2 to 3-40 in Table : 5 were obtained in the same manner as mentioned above, using the corresponding starting materials.
Reference Examples 3-41 to 3-44 } ] A N,N-dimethylacetamide (30 ml) solution containing 4-nitrofluorobenzene (1.69 g) and trans-1,4-cyclohexane- diamine (4.1 g) was stirred at 144°C for 3 days. After = cooling, an aqueous saturated potassium carbonate solution was added to the reaction solution, and the reaction mixture was extracted with ethyl acetate. The extract was dried over anhydrous potassium carbonate, and then, the solvent was removed under reduced pressure. The residue was purified by silica gel flash column chromatography (solvent: chloroform-methanol-ammonia {(90:10:1)), and the
Claims (30)
1. An aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I]: R? rex YY NH-CH=00-N A [1] CN wherein A represents -CH;- or -5-, rR? represents hydrogen atom, a lower alkyl group, a hydroxy lower alkyl group or a lower alkoxy lower alkyl group, X represents -N(R?) -, -0- or -CO-, where R® repre- sents hydrogen atom or a lower alkyl group, and R? represents (1) a cyclic group which may be substituted, where the cyclic group portion is (i) a monocyclic, bicyclic or tricyclic hydrocarbon group, Or (ii) a monocyclic, bicyclic or tricyclic hetero- cyclic group, or (2) an amino group which may be substituted, or a pharmaceutically acceptable salt thereof.
2. The compound according to Claim 1, wherein RZ is (1) a cyclic group which may have 1 to 3 substituents which are the same or different and selected from the substi- tuents of Group A mentioned below, where the cyclic group portion is (i) a monocyclic, bicyclic or tricyclic hydro- carbon group, or (ii) a monocyclic, bicyclic or tricyclic heterocyclic group, cr (2) an amino group which may have 1 or 2 substituents which are the same or different and selected from the substi- tuents of Group B mentioned below. Substituents of Group A:
« -% a halogen atom; cyano group; nitro group; oxo group; hydroxy group; carboxy group; oxidyl group; amino group; carbamoyl group; aminosulfonyl group; a lower alkyl group; a lower alkoxy group; a lower alkanoyl group; a lower alkoxycarbonyl group; a lower alkoxy-substituted lower alkanoyl group; a lower alkoxycarbonyl-substituted lower alkoxy group; a lower alkoxycarbonyl-substituted lower alkoxycarbonyl : group; a lower alkylthio group; a lower alkylsulfonyl group; a di-lower alkylamino-substituted lower alkoxy group; a di-lower alkylaminocarboxy group; a lower alkyl group substituted by a—greup group (8) selected from amino group, carbamoyl group, a halogen atom, hydroxy group, carboxy group, a lower alkoxy group and mono- or di- substituted amino group; a mono- or di-substituted amino group; a mono- or di-substituted carbamoyl group; a substituted or unsubstituted lower cycloalkyl group; a substituted or unsubstituted lower cycloalkyl-CO-; a substituted or unsubstituted lower cycloalkyl-lower alkyl group; a substituted or unsubstituted phenyl group; a substituted or unsubstituted phenyl-0-; a substituted or unsubstituted phenyl-CO-; a substituted or unsubstituted phenyl-lower alkyl group;, a substituted or unsubstituted phenyl-0O-lower alkyl group; a substituted or unsubstituted phenylsulfonyl group; a substituted or unsubstituted phenyl-lower alkoxy group; a substituted or unsubstituted phenyl-lower alkoxycarbonyl group; a substituted or unsubstituted lower cycloalkenyl group; a substituted or unsubstituted bicyclic heterocyclic group; a substituted or unsubstituted monocyclic 5- or 6-membered heterocyclic group;
a substituted or unsubstituted monocyclic 5- or 6-membered heterocyclic group-0-; a substituted or unsubstituted monocyclic 5- or 6-membered heterocyclic group-CO-; a substituted or unsubstituted monocyclic 5- or 6-membered heterocyclic group-CO-lower alkyl group; and : a substituted or unsubstituted monocyclic 5- or 6-membered heterocyclic group-lower alkyl group. Substituents of Group B: a lower alkyl group; a lower alkoxy-substituted lower alkyl group; a lower alkoxycarbonyl-substituted lower alkyl group; a hydroxy lower alkyl group; a carboxy lower alkyl group; a substituted or unsubstituted lower cycloalkyl group; a substituted or unsubstituted lower cycloalkyl-lower alkyl group; a substituted or unsubstituted phenyl group; a substituted or unsubstituted phenyl-lower alkyl group;, a substituted or unsubstituted bicyclic hydrocarbon group; a substituted or unsubstituted monocyclic 5- or 6-membered heterocyclic group; a substituted or unsubstituted monocyclic 5- or 6-membered heterocyclic group-lower alkyl group; and a substituted or unsubstituted bicyclic heterocyclic group- lower alkyl group.
3. The compound according to Claim 2, wherein when the ) ~ nwgybstituent selected from the substituents of Group A" is a mono- or di-substituted amino lower alkyl group, a mono- or di-substituted amino group or a mono- or di-substituted carbamoyl group, then the substituent has substituent(s) selected from the substituents of Group C mentioned below; when the "substituent selected from the substituents of Group A" is a substituted lower cycloalkyl group, a substi- tuted lower cycloalkyl-CO-, a substituted lower cycloalkyl- lower alkyl group, a substituted phenyl group, a substi-
tuted phenyl-0O-, a substituted phenyl-CO-, a substituted phenyl-lower alkyl group, a substituted phenyl-0-lower alkyl group, a substituted phenylsulfonyl group, a substi- tuted phenyl-lower alkoxy group, a substituted phenyl-lower alkoxycarbonyl group, a substituted lower cycloalkenyl group, a substituted bicyclic heterocyclic group, a substi- tuted monocyclic 5- or 6-membered heterocyclic group, a substituted monocyclic 5- or 6-membered heterocyclic group- oo O-, a substituted monocyclic 5- or 6-membered heterocyclic group-CO-, a substituted monocyclic 5- or 6-membered heterocyclic group-CO-lower alkyl group or a substituted monocyclic 5- or 6-membered heterocyclic group-lower alkyl group, then the substituent has substituent (s) selected from a halogen atom, cyano group, nitro group, oxo group and the substituents of Group C mentioned below; and when the "substituent selected from the substituents of Group B" is a substituted lower cycloalkyl group, a substi- tuted lower cycloalkyl-lower alkyl group, a substituted phenyl group, a substituted phenyl-lower alkyl group, a substituted bicyclic hydrocarbon group, a substituted monocyclic 5- or 6-membered heterocyclic group, a substi- tuted monocyclic 5- or 6-membered heterocyclic group-lower alkyl group or a substituted bicyclic heterocyclic group- lower alkyl group, then the substituent has substituent(s) selected from the substituents of Group C mentioned below.
Substituents of Group C: a lower alkyl group; a hydroxy - lower alkyl group; a lower alkanoyl group; a lower cycloalkylcarbonyl group; a lower alkoxy group; a lower alkoxycarbonyl group; a lower alkyl- : sulfonyl group; a di-lower alkyl-substituted carbamoyl group; a di-lower alkylamino-substituted lower alkanoyl group; a substituted or unsubstituted phenyl group; a substituted or unsubstituted phenyl-O-; a substituted or unsubstituted phenyl-CO-; a substituted or unsubstituted phenyl-lower alkanoyl group;
a substituted or unsubstituted phenyl-lower alkyl group; a substituted or unsubstituted phenyl-lower alkoxy group; a substituted or unsubstituted monocyclic 5. or 6-membered heterocyclic group; a substituted or unsubstituted monocyclic 5- or 6-membered ’ heterocyclic group-0-; a substituted or unsubstituted monocyclic 5- or 6-membered heterocyclic group-CO-; and a substituted or unsubstituted monocyclic 5- or 6-membered heterocyclic group-substituted amino group; (in the substituents of Group C, a substituent in the substituted phenyl group portion or the substituted monocyclic 5- or 6-membered heterocyclic group portion is selected from a halogen atom, cyano group, nitro group, oxo group, a lower alkyl group, a lower alkoxy group, a lower alkanoyl group and a lower alkoxycarbonyl group).
4. The compound according to any one of Claims 1 to 3, wherein R? is (1) a cyclic group which may be substituted, where the cyclic group portion is a group selected from the following (i) to (iw) (i) a monocyclic hydrocarbon group having 3 to 7 carbon atoms, (ii) a bicyclic hydrocarbon group having 9 to 11 carbon atoms, - (iii) a monocyclic heterocyclic group containing 1 or 2 hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom, and (iv) a bicyclic heterocyclic group containing 1 to 3 hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom and comprising two 5- to 7-membered rings being fused; or (2) a substituted amino group.
5. The compound according to Claim 4, wherein R? is
(1) a cyclic group which may be substituted, where the cyclic group portion is a group selected from phenyl group, cyclohexyl group, cyclopentyl group, cyclobutyl group, cyclopropyl group, an indanyl group, an indenyl group, a naphthyl group, tetrahydronaphthyl, a pyrrolidinyl group, an imidazolidinyl group, a pyrazolidin- yl group, an oxolanyl group, a thiolanyl group, a pyrrolin- yl group, an imidazolinyl group, a pyrazolinyl group, a pyrrolyl group, an imidazolyl group, a pyrazolyl group, a triazolyl group, a tetrazolyl group, a furyl group, an oxazolyl group, an isoxazolyl group, an oxadiazolyl group, a thienyl group, a thiazolyl group, an isothiazolyl group, a thiadiazolyl group, a piperidyl group, a piperazinyl group, a morpholinyl group, a thiomorpholinyl group, a pyridyl group, a pyrimidinyl group, a pyrazinyl group, a pyridazinyl group, a pyranyl group, a tetrahydropyridyl group, a dihydreopyridazinyl group, a perhydrcazepinyl group, a perhydrothiazepinyl group, an indolinyl group, an iso- indolinyl group, an indolyl group, an indazolyl group, an isoindolyl group, a benzimidazolyl group, a benzothiazolyl group, a benzoxazolyl group, a benzodioxolanyl group, a benzothienyl group, a benzofuryl group, a thienopyridyl group, a thiazolopyridyl group, a pyrrolopyridyl group, a dihydropyrrolopyridyl group, a quinolyl group, an iso- quinolyl group, a quinoxalinyl group, a guinazolinyl group, a phthalazinyl group, a cinnolinyl group, a chromanyl group, an isochromanyl group, a naphthyridinyl group and partially or completely saturated cyclic groups thereof; or (2) a substituted amino group. 30-
6. The compound according to Claim 5, wherein R? is {1) a cyclic group which may be substituted, where the cyclic group portion is a group selected from the group consisting of phenyl group, cyclohexyl group, a pyrrolidin- yl group, a tetrazolyl group, a furyl group, a thienyl group, a thiazolyl group, a piperidyl group, a piperazinyl
} group, a morpholinyl group, a thiomorpholinyl group, a pyridyl group, a pyrimidinyl group, a pyrazinyl group, a pyridazinyl group, a perhydroazepinyl group, an indolinyl group, an isoindolinyl group, a benzothienyl group, a thienopyridyl group, a pyrrolopyridyl group, a dihydro- pyrrolopyridyl group, a quinolyl group, an isoquinolyl group, a quinoxalinyl group and partially or completely saturated cyclic groups thereof; or (2) a substituted amino group.
7. The compound according to Claim 6, wherein R? is (1) a cyclic group which may be substituted, where the cyclic group portion is a group selected from the group consisting of a pyrrolidinyl group, a piperidyl group, a piperazinyl group, a morpholinyl group, a thiomorpholinyl group, a Pyridyl group, a pyrimidinyl group, an indolinyl group, an isoindolinyl group, a pyrrolopyridyl group, a dihydro- pyrrolopyridyl group and partially or completely saturated cyclic groups thereof; or (2) a substituted amino group.
8. The compound according to any one of Claims 1 to 3, wherein R? is (1) a cyclic group which may have 1 to 3 substituents which are the same or different and selected from the substitu- ents of Group A" mentioned below, where the cyclic group portion is selected from the group consisting of a pyrrolidinyl group, a piperidyl group, a piperazinyl group, a morpholinyl group, a thiomorpholinyl group, a pyridyl group, a pyrimidinyl group, an indolinyl group, an isoindolinyl group, a pyrrolopyridyl group, a dihydro- pyrrolopyridyl group and partially or completely saturated cyclic groups thereof; or (2) an amino group substituted by 1 or 2 substituents which are the same or different and selected from the substitu-
ents of Group B' mentioned below. Substituents of Group A': a halogen atom, cyano group, nitro group, o0xoc group, carbamoyl group, a lower alkyl group, a lower alkoxy group, a lower alkanoyl group, a lower alkoxycarbonyl group, a. lower alkoxy-substituted lower alkyl group, a mono- or di- substituted amino group, a mono- or di-substituted carbamoyl group, oo a lower cycloalkyl-CO-, ' a substituted or unsubstituted phenyl group, a substituted or unsubstituted phenyl-lower alkyl group, a substituted or unsubstituted monocyclic 5- or 6-membered heterocyclic group, a substituted or unsubstituted monocyclic 5- or 6-membered heterocyclic group-0-, and a substituted or unsubstituted monocyclic 5- or 6-membered heterocyclic group-CO-. Substituents of Group B': a lower alkyl group, a lower cycloalkyl group, a lower alkoxy-substituted lower alkyl group, a pyrimidinyl group, a thiazolyl group and a thiadiazolyl group.
9. The compound according to any one of Claims 1 to 8, wherein X is -N(R?)- or -0-, and R® is a cyclic group which may be substituted.
10. The compound according to any one of Claims 1 to 8, wherein X is -CO-, and R? is (1) a monocyclic, bicyclic or tricyclic nitrogen-containing heterocyclic group which may be substituted or (2) an amino group which may be substi- tuted, and represented by the formula: N—
11. The compound according to any one of Claims 1 to 8,
wherein X is -CO- or -0-, and A is -CH,-.
12. The compound according to any one of Claims 1 to 8, wherein X is -CO- or -0-, A is -CH,-, and R! is hydrogen atom,
13. The compound according to any one of Claims 1 to 8, wherein X is -CO-, A is -CH,-, and R! is hydrogen atom.
14. The compound according to any one of Claims 1 to 8, wherein X is -CO-, A is -CH,-, R' is hydrogen atom, and R? is a cyclic group which may be substituted.
15. The compound according to any one of Claims 1 to 8, wherein X is -CO-, A is -CH,-, R! is hydrogen atom, and R? is a substituted amino group.
16. The compound according to any one of Claims 1 to 15 which has a partial structure shown below. 1 Rg — Xn Od NH—
17. A compound selected from the group consisting of: (S) -2-cyano-1-[trans-4-(5-nitro-2-pyridylamino) - cyclohexylaminoc]acetylpyrrolidine; (S) -2-cyano-1-[trans-4-(5-cyano-2-pyridyloxy)cyclo- hexylaminol]acetylpyrrolidine; : (8) -2-cyano-1-[trans-4-(dimethylaminocarbonyl)cyclo- hexylamino]acetylpyrrolidine; (S)-2-cyano-1-[trans-4- (morpholinocarbonyl)cyclo- hexylamino)acetylpyrrolidine; (8) -2-cyanc-1-[trans-4-(5-bromo-2-pyrimidinyloxy) - cyclohexylaminolacetylpyrrolidine; (S)-2-cyano-1-[trans-4-(5-pyrimidinylaminocarbonyl) - cyclohexylamino]acetylpyrrolidine;
(S) -2-cyano-1-[trans-4- (N-ethyl-N-methoxyethylamino- carbonyl) cyclohexylamino] acetylpyrrolidine; (S) -2-cyano-1-[trans-4- (N-ethyl-N-isopropylamino- carbonyl) cyclohexylamino] acetylpyrrolidine; (S) -2-cyano-1- [trans-4- (N-methyl-N-butylamino- carbonyl) cyclohexylamino]acetylpyrrolidine; ; (S) -2-cyano-1-[trans-4-[(S)-2-methoxymethylpyrroli- din-1-ylcarbonyl]cyclohexylamino] acetylpyrrolidine; (S) -2-cyano-1-[trans-4- (3-carbamoylpiperidino- carbonyl) cyclohexylamino]acetylpyrrolidine; (S)-2-cyano-1-[trans-4-(3-nitro-2-pyridylamino) - cyclohexylamino] acetylpyrrolidine; (S) -2-cyano-1-[trans-4- (4-acetylpiperazin-1-yl- carbonyl) cyclohexylaminolacetylpyrrolidine; (S)-2-cyano-1- [trans-4-(2-isoindelinylcarbonyl) - cyclohexylaminolacetylpyrrolidine; (S)-2-cyanoc-1-{trans-4-[4-(3-pyridylcarbonyl)- piperazin-l-ylcarbonyl]cyclohexylaminolacetylpyrrolidine; (S) -2-cyano-1-{trans-4-[4- (3-thenoyl)piperazin-1-yl- carbonyl] cyclohexylaminolacetylpyrrolidine; (S) -2-cyano-1-{trans-4-[4-(4-chlorophenyl)piperazin- l-ylcarbonyl]cyclohexylaminoclacetylpyrrolidine; (S)-2-cyano-1- [trans-4-(cis-2,6-dimethylmorpholino- carbonyl) cyclohexylamino] acetylpyrrolidine; (S) -2-cyano-1- [trans-4-{5-nitro-2-isoindolinyl- carbonyl) cyclohexylamino] acetylpyrrolidine; (S)-2-cyano-1- [trans-4- (piperidinocarbonyl)cyclo- hexylamino]acetylpyrrolidine; (8) -2-cyano-1- [trans-4- (4-carbamoylpiperidino- carbonyl) cyclohexylamino] acetylpyrrolidine; (S)-2-cyano-1-[trans-4-(l-pyrrolidinylcarbonyl) - cyclohexylamino]acetylpyrrolidine; (S)-2-cyano-1-[trans-4-(4-cyclopropylcarbonyl- piperazin-1l-ylcarbonyl)cyclohexylamino]acetylpyrrolidine; (S)-2-cyano-1-[trans-4- (4-propionylpiperazin-1-yl- carbonyl) cyclohexylamino]acetylpyrrolidine;
(S) -2-cyano-1-[trans-4-(1-indolinylcarbonyl)cyclo- hexylamino]acetylpyrrolidine; (S) -2-cyano-1-[trans-4-(2,3-dihydro-1H-pyrrolo[3,4- blpyridin-2-ylcarbonyl)cyclohexylamino]acetylpyrrolidine; (S)-2-cyano-1-[trans-4-[4-(2-pyrimidinyloxy) - piperidinocarbonyl]cyclohexylamino]acetylpyrrolidine; (s)-2-cyano-1-{trans-4-[4- (5-bromo-2-pyrimidinyloxy) - piperidinocarbonyl]cyclohexylaminolacetylpyrrolidine; (S)-2-cyano-1-[trans-4-(cis-3,5-dimethyl-4-benzyl- : piperazin-1l-ylcarbonyl)cyclohexylamino]acetylpyrrolidine; (S) -2-cyano-1- [trans-4- (4-cyclohexylcarbonylamino- piperidinocarbonyl)cyclohexylamino]acetylpyrrolidine; (S) -2-cyano-1-{trans-4-[4- (N-phenylcarbamoyl) - piperazin-1l-ylcarbonyl]cyclohexylaminolacetylpyrrolidine; (S)-2-cyano-1-[trans-4- (4-ethoxycarbonylpiperazin-1- yYlcarbonyl)cyclohexylamino] acetylpyrrolidine; (8S) -2-cyano-1-{trans-4-{4-{(2-thienyl)piperidino- carbonyl] cyclohexylaminec] acetylpyrrolidine; (S) -2-cyano-1-[trans-4-(1,1-dioxoperhydro-1,4- thiazin-4-ylcarbonyl)cyclohexylamino]acetylpyrrolidine; (R) -4-cyano-3-[trans-4- (5-nitro-2-pyridylamino) - cyclohexylamino]acetylthiazolidine; (R) -4-cyano-3- [trans-4-(5-cyano-2-pyridyloxy)cyclo- hexylamino]acetylthiazolidine; (R) -4-cyano-3- [trans-4- (dimethylaminocarbonyl)cyclo- hexylamino]acetylthiazolidine; (R) -4-cyano-3- [trans-4- (2-isoindolinylcarbonyl)cyclo- hexylaminol]acetylthiazolidine; (R) -4-cyano-3-[trans-4- {morpholinocarbonyl)cyclo- hexylamino]acetylthiazolidine; and (R) -4-cyano-3- [trans-4- (pyrrolidinylcarbonyl)cyclo- hexylaminol]acetylthiazolidine; or a pharmaceutically acceptable salt thereof.
18. A method for preparing an aliphatic nitrogen- containing 5-membered ring compound represented by the formula [I]: R? aN ex Yomorcon™S CN : wherein A represents -CH,- or -S-, rR! represents hydrogen atom, a lower alkyl group, a hydroxy lower alkyl group or a lower alkoxy lower alkyl group, X represents -N(R’)-, -O- or -CO-, where R® repre- sents hydrogen atom or a lower alkyl group, and R? represents (1) a cyclic group which may be substituted, where the cyclic group portion represents (i) a monocyclic, bicyclic or tricyclic hydrocarbon group, or {ii) a monocyclic, bicyclic or tricyclic heterocyclic group, or (2) an amino group which may be substituted, or a pharmaceutically acceptable salt thereof, which comprises reacting a compound represented by the formula [II]: 1 PN Z —CHy—CO-—-N A il I] : 20 CN wherein A has the same meaning as defined above and 7! represents a reactive residue, with a compound represented by the formula [III]: R? R2—X— NH, [III] wherein R!, X and R? has the same meaning as defined above,
or a salt thereof, and optionally making the product into a pharmaceutically acceptable salt thereof.
19. A method for preparing an aliphatic nitrogen-contain- ing 5-membered ring compound represented by the formula [I-a]: eco Ynn-CHe-co—y A = CN wherein A represents -CH,- or -S-, R! represents hydrogen atom, a lower alkyl group, a hydroxy lower alkyl group or a lower alkoxy lower alkyl group, and R?*! represents (1) a monocyclic, bicyclic or tricyclic nitrogen-containing heterocyclic group, which may be substituted or (2) an amino group which may be substituted, and represented by the formula: { N— NE or a pharmaceutically acceptable salt thereof, which comprises reacting a compound represented by the formula [IV]: . ot ooo) y-oteoony AY) R? CN wherein A and R! have the same meanings as defined above and R* represents a protective group for an amino group, or a salt thereof with the compound represented by the formula [V]: R*-H [vl wherein R** has the same meaning as defined above, or a salt thereof to obtain a compound represented by the ~~ formula (vil: : R! 21_ | VN : R co Yn-ote-co—y A [VI] 4 / R CN wherein R', RY, R*! and A have the same meanings as defined above, } or a salt thereof, and subsequently removing the protective ~~ group for an amino group R*, and optionally making the : product into a pharmaceutically acceptable salt thereof.
20. A compound according to any one of Claims 1 to 17 for treatment or prophylaxis of a disease which comprises administering to a patient an effective dose.
21. A pharmaceutical composition for treatment or prophylaxis of a disease according to Claim 20, wherein the disease is ‘ expected to be alleviated by inhibiting dipeptidylpeptidase IV activity.
22. A pharmaceutical composition for treatment or prophylaxis - of a disease according to Claim 20, wherein the disease is diabetes.
23. A pharmaceutical composition for treatment or prophylaxis of a disease according to Claim 20, wherein the disease is a type 2 diabetes. :
24. Use of the compound according to any one of Claims 1 to 17 as a pharmaceutically effective ingredient of a medicine. Cn oo EEE AMENDED SHEET . © . B N —- ee ee r—————— HN
25. Use of the compound according to any one of Claims 1 to 17 for the preparation of a medicine.
26. The use according to Claim 24 or 25, wherein the medicine is for the treatment of prophylaxis of a disease that is expected to be improved by inhibiting dipeptidylpeptidase IV activity.
27. The use according to Claim 24 or 25, wherein the medicine is for the treatment or prophylaxis -of diabetes.
28. The use according to Claim 24 or 25, wherein the medicine is for the treatment or prophylaxis of type 2 diabetes.
29. A pharmaceutical composition comprising the compound according to any one of Claims 1 to 17 as an effective ingredient, :
30. The pharmaceutical composition according to Claim 29 wherein the pharmaceutical composition is a dipeptidylpeptidase IV inhibitor. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000312562 | 2000-10-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200302030B true ZA200302030B (en) | 2003-09-26 |
Family
ID=32844029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200302030A ZA200302030B (en) | 2000-10-12 | 2003-03-13 | Aliphatic nitrogen-containing 5-membered ring compound. |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200302030B (en) |
-
2003
- 2003-03-13 ZA ZA200302030A patent/ZA200302030B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2312472T3 (en) | ALIFATIC COMPOUND OF FIVE RING MEMBERS CONTAINING NITROGEN. | |
JP4227660B2 (en) | Proline derivatives and their use as dipeptidyl peptidase IV inhibitors | |
JP4329381B2 (en) | Pharmaceutical composition | |
JP4329290B2 (en) | Aliphatic nitrogen-containing five-membered ring compounds | |
JP5154609B2 (en) | Method for assaying effect of test substance on PTH production | |
US7635698B2 (en) | Compounds useful as chemokine receptor antagonists | |
JP2021020939A (en) | Substituted pyrazole compounds as serine protease inhibitors | |
CN101565420B (en) | Limk2 inhibitors, compositions comprising them, and methods of their use | |
US20130123270A1 (en) | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists | |
AU2012300246A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
WO2006098342A1 (en) | Piperazinyl compounds | |
WO2004111041A1 (en) | Pyrrolidine, thiazolidine and oxazolidine compounds which inhibit dipeptidyl peptidase-iv (dpp) | |
CA2557785A1 (en) | Hiv integrase inhibitors | |
CN110944990A (en) | TLR7/8 antagonists and uses thereof | |
US20020119962A1 (en) | Novel urea compounds, compositions and methods of use and preparation | |
EP0721941A1 (en) | Novel compound having platelet aggregation inhibitor effect | |
CN101006097B (en) | Vla-4 antagonists | |
CN101163472A (en) | Vla-4 antagonists | |
WO2007037518A9 (en) | Mutilin derivative and pharmaceutical composition containing the same | |
JP2004035574A (en) | Aliphatic nitrogenous five-membered ring compound | |
ZA200302030B (en) | Aliphatic nitrogen-containing 5-membered ring compound. | |
AU2017244138A1 (en) | Compounds for the inhibition of cyclophilins and uses thereof | |
JP4937506B2 (en) | Novel arylamidine derivatives or salts thereof | |
CN114401722A (en) | Inhibitors of tyrosine kinases | |
KR100848490B1 (en) | 1,2,5-triazepane derivatives having ?-amino acyl group, its pharmaceutical acceptable salts and preparation process thereof |